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A B S T R A C T
Background
Epilepsy is one of the most common neurological disorders. It is estimated that up to 30% of patients with epilepsy continue to have
epileptic seizures despite treatment with an antiepileptic drug. These patients are classified as drug-resistant and require treatment with
a combination of multiple antiepileptic drugs. Brivaracetam is a third-generation antiepileptic drug that is a high-affinity ligand for
synaptic vesicle protein 2A. This review investigates the use of brivaracetam as add-on therapy for epilepsy.
Objectives
To evaluate the efficacy and tolerability of brivaracetam when used as add-on treatment for people with drug-resistant epilepsy.
Search methods
We searched the following databases on 9 October 2018: the Cochrane Register of Studies (CRS Web), which includes the Cochrane
Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); Medline (Ovid) 1946 to
8 October 2018; ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (
ICTRP). Originally we also searched SCOPUS as a substitute for Embase, but this is no longer necessary, because randomised and
quasi-randomised controlled trials in Embase are now included in CENTRAL.
Selection criteria
We sought randomised controlled trials with parallel-group design, recruiting people of any age with drug-resistant epilepsy.We accepted
studies with any level of blinding (double-blind, single-blind, or unblind).
Data collection and analysis
In accordance with standard methodological procedures expected by the Cochrane Collaboration, two review authors independently
assessed trials for inclusion before evaluating trial quality and extracting relevant data. The primary outcome to be assessed was 50%
or greater reduction in seizure frequency. Secondary outcomes were: seizure freedom, treatment withdrawal for any reason, treatment
withdrawal due to adverse events, the proportion of participants who experienced any adverse events, and drug interactions. We used
an intention-to-treat (ITT) population for all primary analyses, and we presented results as risk ratios (RRs) with 95% confidence
intervals (CIs).
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Main results
The review included six trials representing 2411 participants. Only one study included participants with both focal and generalised
onset seizures; the other five trials included participants with focal onset seizures only. All six studies included adult participants between
16 and 80 years old, and treatment periods ranged from 7 to 16 weeks. We judged two studies to have low risk of bias and four to
have unclear risk of bias. One study failed to provide details on the method used for allocation concealment, and one did not report all
outcomes prespecified in the trial protocol. One study did not describe how blinding was maintained, and another noted discrepancies
in reporting.
Participants receiving brivaracetam add-on were significantly more likely to experience a 50% or greater reduction in seizure frequency
than those receiving placebo (RR 1.81, 95% CI 1.53 to 2.14; 6 studies; moderate-quality evidence). Participants receiving brivaracetam
were also significantly more likely to attain seizure freedom (RR 5.89, 95%CI 2.30 to 15.13; 6 studies; moderate-quality evidence). The
incidence of treatment withdrawal for any reason (RR 1.27, 95% CI 0.94 to 1.74; 6 studies; low-quality evidence), as well as the risk of
participants experiencing one or more adverse events (RR 1.08, 95% CI 1.00 to 1.17; 5 studies; moderate-quality evidence), was not
significantly different following treatment with brivaracetam compared to placebo. However, participants receiving brivaracetam did
appear to be significantly more likely to withdraw from treatment specifically because of adverse events compared with those receiving
placebo (RR 1.54, 95% CI 1.02 to 2.33; 6 studies; low-quality evidence).
Authors’ conclusions
Brivaracetam, when used as add-on therapy for patients with drug-resistant epilepsy, is effective in reducing seizure frequency and can aid
patients in achieving seizure freedom. However, add-on brivaracetam is associated with a greater proportion of treatment withdrawals
due to adverse events compared with placebo. It is important to note that only one of the eligible studies included participants with
generalised epilepsy. None of the studies included participants under the age of 16, and all studies were of short duration. Consequently,
these findings aremainly applicable to adult patients with drug-resistant focal epilepsy. Future research should thus focus on investigating
the tolerability and efficacy of brivaracetam during longer-term follow-up, and should also assess the efficacy and tolerability of add-
on brivaracetam in managing other types of seizures and its use in other age groups.
P L A I N L A N G U A G E S U M M A R Y
Brivaracetam add-on therapy for drug-resistant epilepsy
Background
Epilepsy is a disorder characterised by multiple seizures. Most people can control their epilepsy with a single antiepileptic drug; however,
some people require multiple antiepileptic drugs. These people are said to have drug-resistant epilepsy. Brivaracetam is an antiepileptic
drug that can be taken as add-on treatment with another antiepileptic medication to try to manage drug-resistant epilepsy.
Aim of the review
This review aimed to determine whether brivaracetam is effective and tolerable when used as add-on treatment for people with drug-
resistant epilepsy.
Results
Wewere able to identify six studies that investigated brivaracetam as add-on treatment for drug-resistant epilepsy. These studies included
a total of 2411 participants, aged 16 to 80. Most participants had focal epilepsy (i.e. epilepsy that originates in one area of the brain).
People who received brivaracetam in addition to their normal antiepileptic medication were almost twice as likely to experience a 50%
or greater reduction in the frequency of their seizures compared to people who were given placebo (i.e. a fake, inactive drug that should
not affect epilepsy). People who received brivaracetam were also nearly six times more likely to achieve freedom from all seizures than
those receiving placebo. People who received brivaracetam were more likely to withdraw from studies due to side effects, but they were
not actually more likely to experience side effects when compared to people receiving placebo.
Quality of the evidence
Evidence taken from studies examining the effectiveness of brivaracetam was of moderate quality. This means that we can be fairly
certain that study findings showing that brivaracetam is effective in reducing the frequency of seizures in drug-resistant epilepsy are
accurate. Evidence regarding the tolerability of brivaracetam, for example, the number of people who withdrew from these studies and
2Brivaracetam add-on therapy for drug-resistant epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the number of people who experienced side effects, however, was of low quality. This means that we cannot be sure that trial findings
are completely accurate, and that more research is needed to fully investigate the tolerability of brivaracetam. All study participants
were adults, and most had focal epilepsy. As a result, the review cannot inform us about how effective brivaracetam is in children or in
individuals with other types of epilepsy, for example, generalised epilepsy, which is epilepsy that involves the whole brain.
Evidence is current to October 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Brivaracetam compared to placebo for add-on therapy for focal epilepsy
Patient or population: pat ients with drug-resistant focal epilepsy
Setting: outpat ients
Intervention: brivaracetam (all doses)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with brivaracetam
50% or greater re-
duction in seizure
frequency (responder
rate)
Follow-up (range): 7 to
16 weeks
Study population RR 1.81
(1.53 to 2.14)
2411
(6 RCTs)
⊕⊕⊕©
MODERATEa
Brivaracetam likely in-
creases the 50% re-
sponder rate
189 per 1000 342 per 1000
(289 to 404)
Seizure freedom
Follow-up (range): 7 to
16 weeks
Study population RR 5.89
(2.30 to 15.13)
2411
(6 RCTs)
⊕⊕⊕©
MODERATEa,b,c
Brivaracetam likely re-
sults in a large increase
in the number of pa-
t ients achieving seizure
f reedom
4 per 1000 26 per 1000
(10 to 66)
Treatment withdrawal
Follow-up (range): 7 to
16 weeks
Study population RR 1.27
(0.94 to 1.74)
2411
(6 RCTs)
⊕⊕©©
LOWa,b
Brivaracetam might in-
crease treatment with-
drawal slight ly71 per 1000 90 per 1000
(67 to 124)
Proportion of partici-
pants who experienced
adverse events lead-
ing to treatment with-
drawal
Follow-up (range): 7 to
Study population RR 1.54
(1.02 to 2.33)
2411
(6 RCTs)
⊕⊕©©
LOWa,b
Brivaracetam may in-
crease the propor-
t ion of part icipants
who experience ad-
verse events leading to
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16 weeks treatment withdrawal
39 per 1000 60 per 1000
(40 to 91)
Proportion of partici-
pants who experienced
any adverse events
Follow-up (range): 7 to
16 weeks
Study population RR 1.08
(1.00 to 1.17)
2011
(5 RCTs)
⊕⊕⊕©
MODERATEa
Brivaracetam probably
slight ly increases the
proport ion of part ici-
pants who experience
any adverse events
598 per 1000 646 per 1000
(598 to 700)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once for risk of bias: all studies were pharmaceut ical sponsored and some included studies had incomplete
methodological information.
bDowngraded once for imprecision: number of events does not suf f ice for opt imal information size.
cUpgraded once for large ef fect: large ef fect size (RR > 5) observed for outcome.
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B A C K G R O U N D
Description of the condition
Epilepsy is a chronic neurological disorder that is characterised by
recurrent seizures. These seizures are caused by sudden, usually
brief, excessive electrical discharges within a group of neurons.
More than 50 million people in the world today have received a di-
agnosis of epilepsy, and approximately 2.4million new cases occur
each year, worldwide (WHO2013). Antiepileptic drugmonother-
apy is generally accepted as the preferred initial management ap-
proach in epilepsy care. However, up to 30% of individuals with
epilepsy do not respond adequately to conventional antiepileptic
drug treatment, either due to recurrent seizures despite optimised
antiepileptic drug therapy, or due to adverse effects (Van Paesschen
2013). Many of these people will use add-on therapies. There-
fore there is a clear need for antiepileptic drugs that can control
the seizures of those who do not respond to conventional drug
treatment. As a result, dozens of novel antiepileptic drugs have
been marketed in the past two decades, and it is therefore very
important that researchers assess the efficacy and tolerability of
new antiepileptic drugs for all individuals.
Description of the intervention
Brivaracetam is a novel antiepileptic drug that has been investi-
gated as add-on therapy for epilepsy. Brivaracetam is a third-gen-
eration antiepileptic agent that shares a similar chemical struc-
ture with levetiracetam and piracetam. Brivaracetam has been
shown to have a wider antiepileptic spectrum and higher effi-
cacy than levetiracetam in several animal models of structural and
genetic epilepsy (Schulze-Bonhage 2011). In 2005, brivaracetam
was approved as an orphan drug for the treatment of progressive
myoclonus epilepsies by the European Commission (Chu-Shore
2010). In the same year, the US Food and Drug Administra-
tion (FDA) also approved brivaracetam as a treatment for symp-
tomatic myoclonus (Johannessen Landmark 2008). Brivaracetam
has been shown to suppress generalised photoparoxysmal elec-
troencephalography (EEG) responses in a photosensitivity model
as proof-of-principle of its efficacy in patients with epilepsy
(Kasteleijn-NolstTrenité 2007). Brivaracetamwaswell tolerated as
add-on therapy in adults with drug-resistant focal-onset seizures,
but it failed to show consistent efficacy in decreasing the frequency
of seizures in phase IIb and phase III randomised controlled trials
(French 2010; Van Paesschen 2013; Werhahn 2010).
Brivaracetam exhibits linear pharmacokinetics across a wide dose
range (10 mg to 600 mg) when administrated as a single oral
dose to healthy subjects. It is rapidly and completely absorbed
and is weakly bound to plasma proteins (≤ 20%), with an elim-
ination half-life of seven to eight hours after oral administra-
tion (Schulze-Bonhage 2011). Brivaracetam is metabolised pri-
marily via hepatic hydrolysis of the acetamide group, and secondar-
ily through hydroxylation mediated by cytochrome P450 (CYP)
2C19 (Nicolas 2012). It is extensively eliminated renally within
72 hours of ingestion (> 95%). In patients with hepatic impair-
ment, total body clearance of brivaracetam is reduced and plasma
half-life is accordingly prolonged. However, the pharmacokinetic
profile of brivaracetam in patients with renal impairment is similar
to that in healthy participants (von Rosenstiel 2007). Researchers
observed a slight decrease in plasma carbamazepine levels and a
2.5-fold increase in plasma carbamazepine-epoxide levels when
brivaracetam was applied with other antiepileptic drugs at 400
mg per day. In addition, peak concentrations of a single dose of
600 mg phenytoin were decreased slightly when co-administered
with brivaracetam (Schulze-Bonhage 2011). The manufacturers
of brivaracetam have claimed that evidence from phase II/III trials
has shown that no dose adjustment is required when brivaracetam
is added to treatment with other antiepileptic drugs (Bialer 2010).
How the intervention might work
Brivaracetam is a high-affinity synaptic vesicle protein SV2A lig-
and that is involved in presynaptic transmitter release. It shows
inhibition of neuronal voltage-dependent sodium (Na+) channels
(French 2010; Schulze-Bonhage 2011; Van Paesschen 2013).
Why it is important to do this review
To our knowledge, this is the first Cochrane systematic review
that focuses on the use of brivaracetam as add-on therapy for
epilepsy.We summarise here available evidence on the efficacy and
tolerability of brivaracetam as derived from randomised controlled
trials.
O B J E C T I V E S
To evaluate the efficacy and tolerability of brivaracetam when used
as add-on treatment for people with drug-resistant epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials were required to meet all of the following criteria.
1. Randomised controlled trials using an adequate method of
concealment of randomisation (e.g. allocation of sequentially
6Brivaracetam add-on therapy for drug-resistant epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
numbered, sealed packages of medication; sealed, opaque
envelopes; telephone randomisation). We excluded quasi-
randomised controlled trials in which treatment allocation was
decided through methods such as alternate days of the week.
2. Double-blind, single-blind, or unblinded.
3. Placebo-controlled or active-controlled.
4. Parallel-group design.
Types of participants
People of any age with drug-resistant focal-onset seizures (sim-
ple focal, complex focal, or secondary generalised tonic-clonic
seizures) or generalised-onset seizures.
Types of interventions
1. The experimental group consisted of participants who
received brivaracetam in addition to an existing antiepileptic
drug regimen taken at the time of randomisation.
2. The control group consisted of participants who received a
matched placebo or active comparator in addition to an existing
antiepileptic drug regimen taken at the time of randomisation.
Types of outcome measures
Primary outcomes
50% or greater reduction in seizure frequency (responder
rate)
The proportion of individuals with a 50% or greater reduction
in seizure frequency during the treatment period compared with
the pre-randomisation baseline period was our primary outcome.
This outcome was commonly reported in this type of study and
could be calculated for studies that did not report it, provided that
baseline seizure data were recorded.
Secondary outcomes
1. Seizure freedom: the proportion of participants with
complete cessation of seizures at the end of the follow-up period.
2. Treatment withdrawal: the proportion of participants
having treatment withdrawn, for any reason, during the course
of the treatment period. This provides a measure of global
effectiveness. Treatment is likely to be withdrawn due to adverse
effects, lack of efficacy, or a combination of both. This is an
outcome to which the individual makes a direct contribution. In
trials of short duration, it is likely that adverse effects will be the
most common reason for withdrawal.
3. Adverse events:
i) The proportion of participants who experienced
adverse events leading to treatment withdrawal.
ii) The proportion of participants who experienced any
adverse events.
4. Drug interactions: any drug interactions reported in the
included studies.
Search methods for identification of studies
Electronic searches
Searches for this review were first run in April 2013. Subsequent
searches were run in March 2015 and March 2017. The most
recent searches were run on 9 October 2018, when we searched
the following databases, with no language restrictions:
1. Cochrane Register of Studies (CRS Web), which includes
the Cochrane Epilepsy Group Specialized Register and the
Cochrane Central Register of Controlled Trials (CENTRAL),
using the search strategy set out in Appendix 1.
2. Medline (Ovid), 1946 to 08 October 2018, using the
search strategy set out in Appendix 2.
3. ClinicalTrials.gov, using the search strategy set out in
Appendix 3.
4. World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP), using the search strategy set
out in Appendix 4.
Originally, we also searched SCOPUS as a substitute for Embase,
but this is no longer necessary because randomised and quasi-ran-
domised controlled trials in Embase are now included in CEN-
TRAL.
Searching other resources
We reviewed the reference lists of retrieved studies to check for
additional reports of relevant studies.We also contactedUCB, Inc.
(manufacturers of brivaracetam) and epilepsy experts for ongoing
studies and unpublished information.
Data collection and analysis
Selection of studies
The process of selecting studies for inclusion in the review in-
volved merging search results using reference management soft-
ware and removing duplicates of the same report. Two review au-
thors (RB and MP) screened all titles, abstracts, and keywords of
publications identified by the searches to assess trial eligibility. We
excluded publications describing studies that clearly did not meet
the inclusion criteria at this stage. We retrieved all potentially rele-
vant papers, and two review authors (RB and MP) independently
evaluated the full text of each paper, according to pre-specified
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selection criteria. We resolved disagreements by discussion. If dis-
agreements persisted, the third review author (AGM) arbitrated.
Data extraction and management
Two review authors (RB andMP) independently extracted the fol-
lowing information from included trials, if available. We resolved
disagreements by discussion.
1. Methods
i) Study design
ii) Method of randomisation
iii) Allocation concealment
iv) Blindness
v) Study duration
2. Participants
i) Age
ii) Gender
iii) Ethnicity
iv) Type of seizure
v) Seizure frequency
vi) Epilepsy duration
vii) Inclusion criteria
viii) Exclusion criteria
ix) Total number of participants recruited
x) Total number of participants randomised
3. Interventions
i) Dosage
ii) Administration method
iii) Treatment duration
iv) Number of background drugs
4. Outcomes
i) Primary outcome
ii) Secondary outcomes
iii) Adverse events
iv) Drug interactions
5. Follow-up data
i) Duration of follow-up period
ii) Total number of participants followed up
iii) Number of losses to follow-up
iv) Reasons for treatment withdrawal
Assessment of risk of bias in included studies
Two review authors (RB and MP) independently assessed the risk
of bias associated with included studies using the Cochrane ’Risk
of bias’ tool, as outlined in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). The Cochrane ’Risk
of bias’ tool comprises seven specific parameters: (1) random se-
quence generation, (2) allocation concealment, (3) blinding of
participants and personnel, (4) blinding of outcome assessors, (5)
incomplete outcome data, (6) selective outcome reporting, and
(7) other bias. For each entry, review authors made the judgement
(’low’ risk of bias, ’high’ risk of bias, or ’unclear’ risk of bias) and
provided support for the decision by an agreed review author com-
ment or by a quote taken from the corresponding publication.
We then determined an overall judgement for risk of bias within
each study, again in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Specifically, if
we deemed a study to have an unclear risk of bias for one or more
of the key domains, then we awarded that study an overall unclear
risk of bias judgement. Accordingly, if we determined that a study
had high risk of bias for one or more of the key domains, we
awarded that study a high risk of bias judgement overall. Only if
we judged a study to have low risk of bias across all seven domains
did we award that study a low risk of bias judgement overall. We
resolved any disagreements by discussion.
Measures of treatment effect
For dichotomous data, we used the risk ratio (RR) with 95%
confidence interval (CI) for analysis.
For drug interactions, we described the outcome narratively.
Unit of analysis issues
According to guidance provided in the Cochrane Handbook for
Systematic Reviews of Interventions (Deeks 2011), we did not en-
counter any unit of analysis issues.
Dealing with missing data
If data were insufficient or missing, we contacted the manufactur-
ers and original investigators of relevant trials for additional infor-
mation through personal communication. If we did not receive a
response, we analysed available data according to the intention-
to-treat (ITT) principle.
Assessment of heterogeneity
We evaluated clinical and methodological heterogeneity among
trials by comparing the characteristics of participants (age, gen-
der, seizure type, seizure frequency, duration of epilepsy), inter-
ventions (dosage, administration method and duration, co-treat-
ments), and study design (randomisation, allocation concealment,
blinding methods) between studies.
We evaluated statistical heterogeneity among trials using the Chi²
test with significance set at 0.1 along with the I² statistic.
A P value greater than 0.1 in the Chi² test (P > 0.1) indicated no
significant statistical heterogeneity (Deeks 2011).
If a P value was less than or equal to 0.1 in the Chi² test, we
interpreted heterogeneity according to percentage ranges of the I²
statistic, as follows (Deeks 2011).
1. 0% to 40%: might not be important.
2. 30% to 60%: may represent moderate heterogeneity*.
3. 50% to 90%: may represent substantial heterogeneity*.
4. 75% to 100%: represents considerable heterogeneity*.
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*The importance of the observed value of the I² statistic depends
on (1) the magnitude and direction of effect and (2) the strength
of evidence for heterogeneity (e.g. P value from the Chi² test or
confidence interval for the I² statistic).
Assessment of reporting biases
We had originally planned to assess funnel plot asymmetry. Rea-
sons for asymmetry include publication bias, outcome reporting
bias, language bias, citation bias, poor methodological design, and
heterogeneity. Unfortunately, however, our review included fewer
than 10 studies; as a consequence, funnel plots would have been
minimally informative. Therefore, we did not generate funnel
plots as part of this review.
Data synthesis
We analysed the data using Review Manager version 5.3 (RevMan
2014). Heterogeneity determined the choice of a fixed-effect or a
random-effectsmodel. If clinically appropriate, and if we found no
evidence of substantial statistical heterogeneity using the I² statistic
(I² < 50%), we analysed data in a meta-analysis using a fixed-
effect model. If we found substantial heterogeneity (I² ≥ 50%),
we explored possible factors contributing to the heterogeneity and
used a random-effects model to perform meta-analysis.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses according to different dose
groups of brivaracetam, such as 50 mg/d and 100 mg/d, for each
outcome. In addition, we had planned to conduct subgroup anal-
yses according to the different age groups of participants (children
younger than 17 years versus adults); however, all of the studies
exclusively comprised adult populations.
Sensitivity analysis
We had planned to conduct the following sensitivity analyses to
test the robustness of the meta-analysis, where possible.
1. Repeating the analysis with exclusion of unpublished
studies.
2. Repeating the analysis with exclusion of studies published
only as abstracts.
This sensitivity analysis was not required to be conducted in the
current review, as all included studies were published journal arti-
cles.
R E S U L T S
Description of studies
Results of the search
By conducting searches, we identified a total of 186 records for
potential inclusion in the review (Figure 1). We removed 38 du-
plicate records, leaving 148 eligible records. We then discarded 17
of these records due to irrelevance. Of the 131 records remaining,
we excluded a further 106 records at the stage of abstract and title
screening, again due to irrelevance. We attempted to retrieve the
full texts for the 25 records that remained after the initial screening
stage. After accessing and assessing these full-text articles, we de-
termined that 23 records were eligible for inclusion in the review.
All of the 23 records identified were linked to six individual stud-
ies (Biton 2014; French 2010; Klein 2015; Kwan 2014; Ryvlin
2014; Van Paesschen 2013), which we subsequently included in
the meta-analyses.
9Brivaracetam add-on therapy for drug-resistant epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
All six included studies were randomised, double-blind, placebo-
controlled trials, with parallel-group design. We have summarised
the details of the included studies in theCharacteristics of included
studies tables.
Biton 2014 was a multi-centre study, conducted across Australia,
Brazil, Canada, Mexico, and the United States, and including a
total of 400 participants. Participants were aged 16 to 70 and
had drug-resistant focal epilepsy. Most participants were receiving
two concomitant antiepileptic drugs (AEDs) at baseline; however,
some participants were receiving more than three AEDs. Partici-
pants were required to undergo an 8-week baseline period before
randomisation to one of four treatment groups. Participants next
entered a 12-week treatment period, during which they received
5, 20, or 50 mg/d brivaracetam treatment, or matching placebo,
with no up-titration. After completing the trial, participants were
given the option to enter an open-label extension.
French 2010 was, again, a multi-centre study, with sites based in
Brazil, India, Mexico, and the United States. The study included a
total of 208 participants. All participants were between 16 and 65
years of age and had well-characterised focal epilepsy. Participants
were required to be taking one or two concomitant AEDs at base-
line. Similar to Biton 2014, most were receiving two concomitant
AEDs, and a small subset of participants were receiving more than
three AEDs. Eligible participants were randomised to one of four
treatment groups (5, 20, or 50 mg/d brivaracetam or matching
placebo) after completion of the four-week baseline period. The
treatment period was seven weeks long and did not include an up-
titration period. Upon completion of the treatment period, par-
ticipants were offered entry into a long-term open-label extension
study.
Klein 2015, a multi-centre study conducted at sites across North
America, Western Europe, Eastern Europe, Latin America, and
Asia, enrolled and randomised a total of 768 participants. Eligible
participants were between 16 and 80 years of age and had well-
characterised drug-resistant focal epilepsy. Most participants were
receiving two concomitant AEDs at baseline. Only four partic-
ipants (< 1%) were receiving three or more AEDs. Participants
were required to complete an eight-week baseline period before
randomisation. After successful completion of the baseline period,
participants were randomised into one of three treatment groups:
100 mg/d brivaracetam, 200 mg/d brivaracetam, or placebo. Par-
ticipants then undertook a 12-week treatment period, followed by
a four-week down-titration period. Participants were then given
the opportunity to enter an open-label extension study.
Kwan 2014was, likewise, amulti-centre study that recruited a total
of 480 participants from various sites, located in Austria, Belgium,
Czech Republic, Germany, Hong Kong, India, Italy, Norway, Re-
public of South Africa, Russian Federation, Singapore, South Ko-
rea, Sweden, Taiwan, and Ukraine. Participants were aged 16 to
70, and90%haddrug-resistant focal epilepsy. The remaining 10%
had drug-resistant generalised epilepsy. Participants were required
to be taking one to three concomitant AEDs; most participants
were receiving two or more AEDs (45.4%). It is notable that a
much larger proportion of participants in this study (37.3%) were
receiving three or more AEDs compared with the other studies.
Participants completed a four-week baseline period before they
were randomised to one of two treatment arms: 20 to 150 mg/d
brivaracetam or matching placebo, at a ratio of 3:1, respectively.
As a consequence, a much larger number of participants were
randomised to the experimental brivaracetam group than to the
placebo control group. The study consisted of a 16-week treat-
ment period, which comprised an eight-week dose-finding phase
and an eight-week maintenance phase. During the dose-finding
phase, the dosage was up-titrated in a stepwise manner on a two-
weekly basis, dependent on observed efficacy and participants’ tol-
erability. The optimal dose achieved was thenmaintained over the
final eight-week period. After the treatment period, participants
underwent a two-week down-titration period before they were of-
fered entry into one of two open-label follow-up studies.
Ryvlin 2014 was also a multi-centre study, with sites based across
Poland, France, Germany, Spain, Italy, Switzerland, Hungary, Fin-
land, The Netherlands, Belgium, the United Kingdom, and India.
A total of 398 participants were enrolled into the study. All par-
ticipants were aged 16 to 70 and had received a diagnosis of focal
epilepsy. Participants were required to be receiving treatment with
one or two AEDs at baseline, although a small proportion (4%)
were receiving three or more AEDs. After completion of an eight-
week baseline period, participants were randomised to one of four
treatment groups: 20 mg/d brivaracetam, 50 mg/d brivaracetam,
100 mg/d brivaracetam, or placebo. The study comprised a 12-
week treatment period (without up-titration), followed by a two-
week down-titration period, before participants were offered entry
into an open-label extension study.
Van Paesschen 2013 was, again, amulti-centre study. This trial was
conducted at multiple sites across Belgium, Czech Republic, Fin-
land, France, Germany, The Netherlands, Poland, Spain, and the
United Kingdom. A total of 157 participants were recruited into
this study. Participants were aged 16 to 65 and had drug-resistant
focal epilepsy. They were required to be receiving one or two con-
comitant AEDs. Again, the largest proportion of participants were
taking two concomitant AEDs at baseline, with only 6% taking
three or more AEDs. Randomisation took place after completion
of a four-week baseline period. Participants were randomised to
one of three treatment groups: 50 mg/d brivaracetam, 150 mg/
d brivaracetam, or matching placebo. The treatment period con-
sisted of a three-week up-titration followed by a seven-weekmain-
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tenance phase, and therefore lasted 10 weeks. After completion of
the trial, participants were asked whether they wished to enter an
open-label extension study.
Excluded studies
We excluded one study at the full-text screening stage because it
was not an RCT but was instead a meta-analysis of two studies
that had already been included in the review (see Characteristics
of excluded studies) (Lacroix 2007). We were unable to include
another study because the study was ongoing and no results had
so far been published (see Characteristics of ongoing studies) (
NCT03083665). Additionally, it was not fully clear whether this
study was eligible for inclusion because of the limited information
provided regarding study design. If results of the NCT03083665
study have been published by the time of the next review update,
we will reassess this study for inclusion.
Risk of bias in included studies
We judged that two studies had low risk of bias overall (French
2010; Klein 2015), whilst we judged that the other four studies
had unclear risk of bias (Biton 2014; Kwan 2014; Ryvlin 2014;
Van Paesschen 2013). Figure 2 and Figure 3 present summaries
of the ’Risk of bias’ associated with each of the included studies
for each rating domain. We discuss below the individual rating
domains for all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All six studies provided details regarding randomisation of par-
ticipants. We therefore awarded a low risk of bias judgement for
random sequence generation for all included studies. Five stud-
ies specified that randomisation was achieved using the random
permuted blocks method with stratification (Biton 2014; French
2010; Klein 2015; Kwan 2014; Van Paesschen 2013). The remain-
ing study instead used a central randomisation system, although,
again, randomisation was stratified (Ryvlin 2014).
With regards to allocation concealment, three of the included stud-
ies described using an interactive voice response system (IVRS) to
ensure allocation concealment (Biton 2014; Klein 2015; Ryvlin
2014). Meanwhile, two studies used a central randomisation sys-
tem, which, again, enabled allocation to be effectively concealed
(French 2010; Van Paesschen 2013). We judged that these five
studies all had low risk of bias with regards to allocation conceal-
ment. In contrast, we assessed the remaining study to have unclear
risk of bias after study authors failed to describe any methods used
for allocation concealment (Kwan 2014).
Blinding
Five of the included studies were double-blind and specified that
they used matching placebo tablets to maintain blinding (Biton
2014; French 2010; Klein 2015; Kwan 2014; Van Paesschen
2013).One study further described that tablets of various strengths
were used so that all participants took two tablets per dose, regard-
less of their actual randomised dosage of brivaracetam or alloca-
tion to placebo (Klein 2015). This further ensured that blinding
was maintained. All patients and study personnel were adequately
blinded by the matching placebo and, consequently, we assessed
all five studies to be at low risk of performance bias.
Efficacy outcomes were self-reported by patients in seizure di-
aries. Accordingly, patients were regarded as the outcome asses-
sors. As described above, participants were effectively blinded by
the matching placebo and, as a result, their reporting of outcomes
was not affected or biased by treatment allocation. Likewise, be-
cause the studies were double-blind, the investigators, including
those responsible for data analysis, would also have been effec-
tively blinded. We therefore assessed all five studies to have low
risk of bias with regards to detection bias for outcome assess-
ment (Biton 2014; French 2010; Klein 2015; Kwan 2014; Van
Paesschen 2013).
The remaining study - Ryvlin 2014 - did not explain any methods
used tomaintain blinding. Consequently, we assessed this study as
having unclear risk for both performance bias and detection bias.
Incomplete outcome data
We rated all of the included studies to be at low risk of attrition
bias (Biton 2014; French 2010; Klein 2015; Kwan 2014; Ryvlin
2014; Van Paesschen 2013). All six studies reported the attrition
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rate and conducted an ITT analysis. In actuality, however, only
two of these studies utilised a strict ITT population, whereby all
participantswhowere randomisedwere analysed (Kwan 2014;Van
Paesschen 2013). The other four studies instead used a modified
ITT population, most commonly excluding participants who did
not receive at least one dose of study drug (Biton 2014; French
2010; Klein 2015; Ryvlin 2014). For each study, nomore than 1%
of participants were excluded from the ITT population; therefore,
we still assessed studies to be at low risk of attrition bias. All partic-
ipants excluded from ITT analyses conducted within the studies
were reinstated in the ITT analyses performed here, in this review.
Selective reporting
We assessed that four of the included studies were at low risk of re-
porting bias (French 2010; Klein 2015; Kwan 2014; Ryvlin 2014).
Despite not supplying a trial protocol, each of the four studies
reported results for all of the outcome measures prespecified in the
methods section of their respective publications. Another study
similarly reported the results of its prespecified outcomes (Biton
2014); however, study authors failed to provide results for the
placebo group for one of the outcome measures - the number of
participants reporting one ormore adverse events. This introduced
reporting bias and precluded inclusion of this study in the meta-
analysis for that outcome. As a result, the study was deemed to
have unclear risk of reporting bias. The remaining study - Van
Paesschen 2013 - provided a trial protocol; however, not all in-
tended outcomes identified in the trial protocol were reported in
subsequent publications. Again, we assessed this study as having
unclear risk of bias.
Other potential sources of bias
We identified another source of potential bias in the Kwan
2014 study, which randomised participants to the experimental
brivaracetam group and the placebo control group at a ratio of 3:
1, respectively. This produced an uneven distribution of partici-
pants between the two treatment groups. Unequal allocation ra-
tios reduce the statistical power of a trial and negatively impact the
ability of that trial to detect a therapeutic effect (Hey 2014). Kwan
2014 did, however, complete a power calculation and determined
that a sample size of 376 participants would be required to detect a
16% reduction in baseline-adjusted weekly focal seizure frequency
compared to placebo. Kwan 2014 actually recruited 480 partic-
ipants and, therefore, exceeded the estimated sample size. Thus,
this trial should have retained adequate statistical power to be able
to detect a therapeutic effect, despite the unequal allocation ratio.
Nevertheless, unequal allocation ratios are further associated with
a greater placebo effect (Hey 2014). As a result, the unequal alloca-
tion ratio used could still distort the perceived therapeutic effect,
despite the compensatory sample size calculation. For this reason,
we awarded Kwan 2014 an unclear risk of bias with regards to
other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Brivaracetam compared to placebo for add-on therapy for focal
epilepsy
See Summary of findings for the main comparison for the main
comparison: brivaracetamcompared toplacebo for add-on therapy
for focal epilepsy.
Five of the included studies used well-defined, escalated doses of
brivaracetam for the experimental treatment groups (Biton 2014;
French 2010; Klein 2015; Ryvlin 2014; Van Paesschen 2013). In
contrast, the Kwan 2014 study utilised a flexible dosing regimen,
whereby participants began on 20 mg/d brivaracetam or placebo,
and then increased their dose up to 150 mg/d, depending on the
efficacy that they experienced and their tolerability of the study
drug. Although it was reported that most participants in both the
brivaracetam and placebo treatment groups achieved the highest
dosages of 100 mg/d and 150 mg/d, the dose was not standardised
amongst participants. As a result, the data extracted from Kwan
2014 could not be included in the subgroup analysis for drug dose
for any of the outcomes listed.
Notably, and also of importance to the analyses, two of the in-
cluded studies each excluded eight participants from their ITT
populations, despite having randomised these participants to a
treatment group (Biton 2014; Klein 2015). Klein 2015 specified
that participants must have received one or more doses of study
drug andmust have provided at least one post-baseline diary entry,
thus explaining the exclusion of some participants. Biton 2014
stated that participants must have received one or more doses of
study drug, justifying the exclusion of four participants; however,
researchers then excluded an additional four participants - three
due to serious non-compliance and one as a clinical outlier. We
reinstated the 16 excluded participants in the ITT analysis con-
ducted in this review, to ensure that our ITT analysis fully adhered
to the “once randomised, always analysed” principle. We repeated
this for each of the outcomes analysed and reported on this below.
1. 50% or greater reduction in seizure frequency
All six included studies, involving a total of 2411 ITT participants,
contributed to this outcome analysis (Biton 2014; French 2010;
Klein 2015; Kwan 2014; Ryvlin 2014; Van Paesschen 2013). Par-
ticipants receiving brivaracetam were significantly more likely to
achieve a 50% or greater reduction in seizure frequency, compared
to those who received placebo (risk ratio (RR) 1.81, 95% confi-
dence interval (CI) 1.53 to 2.14; Analysis 1.1). Subgroup analysis
by dose of brivaracetam did not suggest any difference in 50% or
greater reduction in seizure frequency dependent on dose. Doses
of 20 mg/d (RR 1.64, 95% CI 1.18 to 2.27), 50 mg/d (RR 2.00,
95%CI 1.50 to 2.66), 100 mg/d (RR 1.81, 95%CI 1.42 to 2.30),
and 200 mg/d (RR 1.76, 95% CI 1.33 to 2.33) brivaracetam were
all associated with a significantly greater proportion of participants
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achieving a 50% or greater reduction in seizure frequency than
placebo (Analysis 1.1).
2. Seizure freedom
All six studies, consisting of 2411 ITT participants, were included
in this outcome analysis (Biton 2014; French 2010; Klein 2015;
Kwan 2014; Ryvlin 2014; Van Paesschen 2013). Participants re-
ceiving brivaracetam were significantly more likely to experience
seizure freedom, specifically, almost six times more likely, than
those receiving placebo (RR 5.89, 95% CI 2.30 to 15.13; Analysis
1.2). We noted no significant heterogeneity within the data set
(Chi² = 0.83, df = 5, P = 0.97, I² = 0%) for seizure freedom.
Subgroup analysis stratified by dose did, however, show that only
participants receiving the higher doses of 50 mg/d (RR 5.39, 95%
CI 1.42 to 20.49), 100 mg/d (RR 7.19, 95% CI 1.93 to 26.85),
and 200 mg/d (RR 5.24, 95% CI 1.16 to 23.68) were signifi-
cantly more likely to achieve seizure freedom than those receiving
placebo.
3. Treatment withdrawal
All six studies, consisting of 2411 ITT participants, reported the
number of treatment withdrawals and thus contributed to this
outcome analysis (Biton 2014; French 2010; Klein 2015; Kwan
2014; Ryvlin 2014; Van Paesschen 2013). They reported no sig-
nificant differences in the proportion of participants withdrawing
from treatment when comparing those randomised to brivarac-
etam and those randomised to placebo (RR 1.27, 95% CI 0.94 to
1.74; Analysis 1.3). This was consistently found in each of the dose
subgroups; no dose of brivaracetam was associated with a signifi-
cantly higher rate of treatment withdrawal compared to placebo.
Notably, however, we detected more heterogeneity within the col-
lective data set, consisting of all doses of brivaracetam (Chi² = 7.32,
df = 5, P = 0.20, I² = 32%), as well as within the individual dose
subgroups during subgroup analysis. This was particularly evident
when compared to the complete absence of heterogeneity observed
in the efficacy outcomes - 50% or greater seizure reduction and
seizure freedom. Heterogeneity was most prominent in the 5 mg/
d (Chi² = 2.36, df = 1, P = 0.12, I² = 58%) and 100 mg/d (Chi² =
2.05, df = 1, P = 0.15, I² = 51%) brivaracetam subgroups, although
it is important to note that the levels of heterogeneity remained
statistically insignificant. Of greatest concern, the direction of ef-
fect varied between studies. French 2010 and Van Paesschen 2013
reported a greater incidence of treatment withdrawal amongst par-
ticipants receiving placebo compared to those receiving brivarac-
etam, whereas Biton 2014 and Klein 2015 reported the opposite,
with more participants randomised to brivaracetam withdrawing
from treatment compared to those randomised to placebo.
4. Adverse events
All six studies, consisting of 2411 ITT participants, reported and
stated the reasons for treatment withdrawal (Biton 2014; French
2010;Klein2015;Kwan 2014;Ryvlin 2014;VanPaesschen2013).
Data from all six studies were therefore included in the outcome
analysis for the proportion of participants who experienced ad-
verse events leading to treatment withdrawal. In contrast to treat-
ment withdrawal for any reason, the analysis showed that receiv-
ing brivaracetam was associated with a significantly higher preva-
lence of participants withdrawing from treatment, specifically due
to adverse events (RR 1.54, 95% CI 1.02 to 2.33; Analysis 1.4),
compared to those receiving placebo. However, it is interesting
to note that subgroup analysis revealed that none of the indi-
vidual doses of brivaracetam were associated with a significantly
higher proportion of treatment withdrawals due to adverse events
than placebo. Furthermore, although not statistically significant,
the data reported regarding 5 mg/d brivaracetam, compared to
placebo, again displayed more heterogeneity (Chi² = 2.12, df = 1,
P = 0.15, I² = 53%) than had been associated with the other out-
comes. Most noticeably, French 2010 again observed the opposite
treatment effect to that reported by the other studies included in
this analysis.
In contrast to the other outcome analyses, only five studies, com-
prising 2011 participants, fully reported the proportion of partic-
ipants who experienced at least one adverse event, and thus con-
tributed to the outcome analysis performed (French 2010; Klein
2015; Kwan 2014; Ryvlin 2014; Van Paesschen 2013). Biton 2014
failed to report the incidence of participants in the placebo group
reporting one or more adverse events and, therefore, was excluded
from the analysis. Results showno significant difference in the pro-
portion of participants experiencing one or more adverse events
when receiving brivaracetam compared to those receiving placebo
(RR 1.08, 95% CI 1.00 to 1.17; Analysis 1.5). Out of the six indi-
vidual doses of brivaracetam tested during the subgroup analysis,
only one dose - 100 mg/d brivaracetam (RR 1.16, 95% CI 1.04
to 1.31) - was associated with a significantly higher proportion of
participants experiencing one or more adverse events compared to
those receiving placebo. The effect size was fairly small, however,
despite being significant. Specifically, there was a 16% increase in
the number of participants reporting one or more adverse events
when receiving 100 mg/d brivaracetam, compared to those receiv-
ing placebo.
5. Drug interactions
Five of the included studies, including 1643 participants, de-
scribed drug interactions in their publications (Biton 2014; French
2010; Kwan 2014; Ryvlin 2014; Van Paesschen 2013). Specif-
ically, all five studies referenced the interaction of brivaracetam
with concomitant levetiracetam use.
Biton 2014 noted that a smaller proportion of participants experi-
enced a 50% or greater reduction in seizure frequency after receiv-
ing brivaracetam if they were using levetiracetam concomitantly.
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Furthermore, Biton 2014 recognised that the median per cent re-
duction from baseline in weekly partial onset seizure frequency
was lower in participants using concomitant levetiracetam.
Equally, French 2010 demonstrated that a reduced proportion
of participants achieved a 50% or greater reduction in seizure
frequency, dependent on concomitant levetiracetamuse.However,
French 2010 was unable to comment on the significance of this
result because of the small number of participants included in the
observation.
Kwan 2014, similarly, reported that only 13% of participants re-
ceiving brivaracetam and taking concomitant levetiracetam expe-
rienced a 50% or greater reduction in seizure frequency compared
to 34%of participants not using concomitant levetiracetam.Kwan
2014 also stated that participants using concomitant levetirac-
etam experienced a smaller baseline-adjusted per cent reduction
in weekly focal seizure frequency than levetiracetam naive partic-
ipants,
Ryvlin 2014 agreed that, generally, a greater proportion of partic-
ipants who were levetiracetam naive or had previously used leve-
tiracetam but since discontinued its use achieved a 50% or greater
reduction in seizure frequency. Likewise, participants concomi-
tantly using levetiracetam in the Ryvlin 2014 study experienced a
lesser reduction in seizure frequency.
Van Paesschen 2013 reported that 26% of participants receiving
brivaracetam and using concomitant levetiracetam attained a 50%
or greater reduction in seizure frequency, as opposed to 32% and
47% of participants with prior levetiracetamuse and levetiracetam
naive participants, respectively. Placebo responses showed the op-
posite trend but were also more consistent. Results show that 27%
of participants receiving placebo and using concomitant levetirac-
etamwere responders, achieving a 50%or greater reduction, whilst
22% of participants who received placebo with prior levetiracetam
use or who were levetiracetam naive were responders.
All five studies consistently reported that a decreased proportion
of participants randomised to brivaracetam achieved a 50% or
greater reduction in seizure frequency when using levetiracetam
concomitantly. These studies also implied that there was an over-
all decrease in the efficacy of brivaracetam with concomitant leve-
tiracetam use, as demonstrated by the smaller reduction in seizure
frequency observed.
D I S C U S S I O N
Summary of main results
This review evaluated the efficacy and tolerability of brivaracetam
when used as an add-on treatment for people with drug-resistant
epilepsy. Six studies, involving 2411 participants, contributed to
the analyses performed in this review (Biton 2014; French 2010;
Klein 2015; Kwan 2014; Ryvlin 2014; Van Paesschen 2013). We
assessed two of the included studies to have low risk of bias (French
2010; Klein 2015), and we deemed that four studies had unclear
risk of bias (Biton 2014; Kwan 2014; Ryvlin 2014; Van Paesschen
2013). Participants receiving brivaracetam were significantly more
likely than those receiving placebo to experience a 50% or greater
reduction in seizure frequency, and to achieve seizure freedom.
Although participants receiving brivaracetam were significantly
more likely to withdraw from treatment due to adverse events
than those receiving placebo, the overall treatment withdrawal
rate (withdrawal for any reason) was not significantly different be-
tween the two treatment groups. Moreover, the incidence of par-
ticipants experiencing one or more adverse events was not signif-
icantly different between participants receiving brivaracetam and
those given placebo. With regards to drug interactions, general
consensus across all five included studies indicates that concomi-
tant levetiracetam use diminishes the efficacy of brivaracetam with
regards to both the responder rate and, more generally, the ob-
served reduction in seizure frequency, despite no statistical analy-
sis.
Subgroup analysis according to dosage suggested that no dose-re-
sponse relationship is associated with brivaracetam use. Notably,
the effect size observed was fairly consistent across all doses. How-
ever, the subgroup analysis did provide some information regard-
ing possible doses of brivaracetam for clinical use. Doses of 50
mg/d, 100 mg/d, and 200 mg/d brivaracetam were all associated
with a significantly higher proportion of participants achieving a
50% or greater reduction in seizure frequency, as well as seizure
freedom, compared to placebo. It is important to note that none
of these doses was associated with a significantly higher treatment
withdrawal rate for any reason or specifically due to adverse events
experienced. A slightly higher incidence of participants report-
ing one or more adverse events was noted with use of 100 mg/
d brivaracetam. It is interesting to note that 150 mg/d brivarac-
etam did not display a significant therapeutic effect compared to
placebo. However, this subgroup yielded limited data, with only
one study, involving only 104 participants, included in the sub-
group analysis (Van Paesschen2013). Consequently, this subgroup
may have been underpowered; this could potentially explain the
lack of efficacy noted.
The conclusions presented here should be applied cautiously due
to the limited numbers of studies and participants included in
each subgroup analysis.
Overall completeness and applicability of
evidence
Although we did perform a subgroup analysis according to dose
groups of brivaracetam, caution must be taken when interpreting
and extrapolating the results. The number of participants included
in each subgroup analysis ranged from 104 to 717 per subgroup
analysis. This highlights that there could be possible inadequacies
in statistical power for some of the subgroup analyses. As a conse-
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quence, this review can provide only limited information regard-
ing the efficacy of specific brivaracetam doses.
We also intended to conduct a subgroup analysis involving the
age of participants. Unfortunately, we were unable to perform this
subgroup analysis as all six of the included studies utilised exclu-
sively adult populations. We are therefore unable to comment on
the efficacy of brivaracetam when used in children. Additionally,
we are unable to adequately discuss the application of brivaracetam
in drug-resistant generalised epilepsy, although we included this
population in the review. Notably, only the Kwan 2014 study in-
cluded participants with drug-resistant generalised epilepsy. Kwan
2014 did state that brivaracetam appeared to be more efficacious
in participants with generalised epilepsy than in those with focal
onset epilepsy. The small sample size of participants with gener-
alised epilepsy, however, precluded any formal statistical analysis
within the study and thus prevented any conclusions from be-
ing drawn. The finding does highlight the potential efficacy of
brivaracetam in generalised epilepsy and emphasises the need for
future research.
Quality of the evidence
We assessed two of the included studies to be at low risk of bias
(French 2010; Klein 2015). Both studies described effective meth-
ods used for randomisation, allocation concealment, and blind-
ing. We did not suspect attrition or reporting bias in either study.
We assessed that the remaining four studies were at unclear risk of
bias (Biton 2014; Kwan 2014; Ryvlin 2014; Van Paesschen 2013).
We awarded each of the four studies an unclear risk of bias rating
for one or two of the risk of bias domains. We assessed all other
domains to be at low risk of bias. One study did not declare the
method used for allocation concealment (Kwan 2014), whilst an-
other study failed to adequately describe any method of blinding
(Ryvlin 2014). We suspected two studies of selective reporting
(Biton 2014; Van Paesschen 2013). Biton 2014 did not report
data for the placebo group for one of the outcomemeasures, whilst
Van Paesschen 2013 did not report all outcomes predefined in the
trial protocol. We further assessed Kwan 2014 to be at unclear risk
of other bias, namely, for using an unequal allocation ratio, which
could lead to an exaggerated placebo effect.
As a result, during GRADE assessment, we downgraded the qual-
ity of evidence once for all outcomes due to concerns about un-
clear risk of bias across four of the included studies. We conse-
quently rated the quality of evidence as moderate for the follow-
ing outcomes: 50% responder rate and proportion of participants
who experienced any adverse events. Notably, we also rated the
quality of evidence for the outcome, seizure freedom, as moderate.
In fact, we again downgraded the quality of evidence for seizure
freedom due to very serious imprecision, resulting from the small
number of events included within the outcome analysis. However,
the downgrading was compensated for by the large effect size ob-
served. This equated to an overall rating of moderate quality. For
the remaining two outcomes - treatment withdrawal for any rea-
son and treatment withdrawal due to adverse events - we rated the
quality of evidence as low. We downgraded both outcomes once
more for imprecision, again because of the small number of events
constituting the analysis. For these two outcomes, the imprecision
noted was not compensated for by a large effect size; consequently,
the evidence remained assessed as of low quality.
We did consider downgrading the quality of evidence once again
with regard to indirectness for all outcomes due to lack of data
concerning the effect of add-on brivaracetam in children and in
patients with generalised epilepsy, specifically.However, we judged
that the data provided by the included studies did sufficiently
answer the original research question, that is, whether brivaracetam
is efficacious and tolerable as an add-on therapy for people with
drug-resistant epilepsy - despite inclusion of no or limited data
about these subgroups of participants. As a result, we did not think
that indirectness was serious enough to permit downgrading the
quality of evidence again. Instead, we emphasise that the findings
reported are applicable only to adults, mainly to those with focal
epilepsy. Findings might not necessarily be relevant or applicable
to adults with generalised epilepsy.
As a result, we can be fairly confident that the conclusions made
with regards to the outcomes - 50% responder rate, seizure free-
dom, and proportion of participants likely to experience any ad-
verse events - are accurate.We are less certain about the accuracy of
our observations concerning treatment withdrawal for any reason
or specifically due to any adverse events experienced.
It is worth noting that all six studies were sponsored by UCB
Pharma, the manufacturer of brivaracetam. Although it does not
contribute to the risk of bias nor to GRADE assessment, this
pharmaceutical sponsorship could potentially lead to funding bias.
However, it is generally accepted that if a study ismethodologically
sound, and if the protocol is correctly adhered to, that study’s
conduct, and therefore findings, should not be affected by funding
bias.
Potential biases in the review process
We are unaware of any sources of bias in our conduct of the review.
As per the review protocol, we (two review authors) independently
assessed the eligibility of studies identified by the search strategies
for inclusion, independently extracted the relevant data, and inde-
pendently completed both risk of bias and GRADE assessments.
We requested all protocols as planned; however, we were provided
with the trial protocol only for the Van Paesschen 2013 study. We
also could not obtain missing data for the Biton 2014 study re-
garding the proportion of participants in the placebo group to ex-
perience one or more adverse events. Although both events could
potentially bias the review, both instances were outside of our con-
trol.
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Agreements and disagreements with other
studies or reviews
The findings of our current review are consistent with the ob-
servations made in other systematic reviews, which similarly as-
sessed the efficacy and tolerability of brivaracetam (Lattanzi 2016;
Ma 2015; Tian 2015). These other systematic reviews likewise re-
ported risk ratios for both the 50% responder rate and the seizure
freedom rate. All review authors similarly concluded that brivarac-
etam is an efficacious add-on therapy for drug-resistant epilepsy.
However, it is important to note that the systematic reviews iden-
tified specifically focused on the use of brivaracetam as an add-on
therapy for drug-resistant focal epilepsy and, therefore, excluded
participants with generalised epilepsy from their analyses. From
this perspective, our review provides additional, novel information
to that available in these other systematic reviews.
As observed here, in two of the reviews, the risk ratio for seizure
freedom demonstrated an especially large effect for brivaracetam
compared to placebo (Lattanzi 2016; Ma 2015). One review also
completed a subgroup analysis according to dosage, and reported
that any dose above 5 mg/d was associated with a significant ther-
apeutic effect. In our review, we similarly observed that all doses
of brivaracetam greater than 5 mg/d were associated with a sig-
nificantly higher responder rate compared to placebo. However,
we instead suggest that doses of 50 mg/d brivaracetam and greater
are efficacious for managing drug-resistant epilepsy. Doses of 50
mg/d and above of brivaracetam were consistently more effective
than placebo across the two efficacy outcomes - responder rate and
seizure freedom. Neither 5 mg/d nor 20 mg/d brivaracetam was
more efficacious than placebo with regard to seizure freedom.
With regards to drug interactions, Lattanzi 2016 further con-
ducted a subgroup analysis to investigate the effect of levetiracetam
status on responsiveness to brivaracetam. In accordance with our
findings, Lattanzi 2016 emphasised that concomitant use of leve-
tiracetam reversed the significant difference in the 50% responder
rate normally observed with add-on brivaracetam.
In addition to confirming the efficacy of brivaracetam, the other
systematic reviews also assessed its tolerability. All three reviews
emphasised that brivaracetam was well tolerated (Lattanzi 2016;
Ma 2015; Tian 2015), and one review reported risk ratios for
treatmentwithdrawal that were very similar to those reported here.
Another review (Zhu 2017), which specifically investigated the
safety and tolerability of brivaracetam, reported that brivaracetam
was not significantly associated with serious adverse events nor
treatment withdrawal for any reason or due to adverse events.
It is interesting to note that within our review, data taken from the
French 2010 study appear to disagree with those from other in-
cluded studies with regards to treatment withdrawal - an outcome
concerning tolerability. Specifically, French 2010 reported that
treatment withdrawal for any reason and due to adverse events was
greater amongst participants randomised to placebo than amongst
those randomised to brivaracetam. Although the number of par-
ticipants withdrawing from treatment during the study was low
overall (placebo: 6 vs brivaracetam: 5), it is interesting to note that
this study also reported the shortest treatment period (7 weeks
vs 10 to 16 weeks in duration). Similarly, Van Paesschen 2013,
which also reported a shorter treatment period compared to the
other studies (10 weeks vs 12 to 16 weeks in duration), likewise
reported a higher withdrawal rate for participants randomised to
placebo compared to brivaracetam for treatment withdrawal for
any reason. Length of the treatment period could thus potentially
explain the heterogeneity observed.
It is apparent that the findings and conclusions of our current re-
view regarding both efficacy and the safety profile of brivaracetam
are consistent with those of currently available systematic reviews.
This consequently generates further support for the argument that
brivaracetam is effective in treating drug-resistant epilepsy when
used as an add-on therapy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate-quality evidence shows that brivaracetam, when used
as an add-on for adults with drug-resistant focal epilepsy, is effec-
tive in reducing seizure frequency and increasing the likelihood of
people achieving seizure freedom. Limited information is available
regarding the efficacy of brivaracetam in adults with drug-resis-
tant generalised epilepsy. However, a small sample trial suggested
that brivaracetam could in fact display increased effectiveness in
this population compared to when it is used in focal epilepsy. Ad-
ditionally, our findings strongly suggest that brivaracetam should
not be used in conjunction with concomitant levetiracetam due
to the reduced efficacy reported.
Our current review suggests that a good tolerability profile is as-
sociated with brivaracetam. Evidence concerning treatment with-
drawal - an important outcome for determining drug safety - was,
however, of low quality and must therefore be interpreted cau-
tiously. In contrast, evidence for the proportion of participants to
experience any adverse events - another outcome that contributes
to drug safety - was of moderate quality and demonstrated only
a relatively slight increase in prevalence. We did not, however, in-
vestigate the prevalence of individual adverse events; this should
be addressed in subsequent reviews.
We must again emphasise that the evidence for this review was
derived from randomised controlled trials that exclusively stud-
ied adult populations, principally adult populations with drug-
resistant focal epilepsy - not with generalised epilepsy. As a result,
overall, this review shows that brivaracetam is a fairly tolerable and
effective drug for use specifically in adults with drug-resistant focal
epilepsy.
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Implications for research
All current conclusions are based on relatively short-term studies
that have largely focused on populations with drug-resistant fo-
cal epilepsy. More trials including participants with drug-resistant
generalised epilepsy are necessary for full assessment of whether
brivaracetam also displays efficacy in this population, as suspected
in this review. Additional trials should aim to incorporate multiple
doses of brivaracetam to help ascertain a recommended specific
dose for clinical use, and should be conducted over longer periods
of time. Long-term studies are required to assess the long-term
safety and tolerability of brivaracetam. After the safety profile of
brivaracetam is ascertained, it would be recommended that addi-
tional studies should be conducted to determine the efficacy of
brivaracetam in children. Together, these additional studies and
subsequent meta-analyses could more accurately inform clinical
practice.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Biton 2014
Methods Study design: phase 3, randomised, double-blind, PBO-controlled, parallel-group,
multi-centre
Countries: Australia, Brazil, Canada, Mexico, and the USA
Duration:
1. Prospective baseline period (8 weeks)
2. Treatment period (12 weeks)
3. Down-titration period (1 week) or entry into long-term open-label follow-up study
Participants Randomised population
BRV 50 mg/d = 102
BRV 20 mg/d = 100
BRV 5 mg/d = 99
PBO = 99
ITT populationa :
BRV 50 mg/d = 101
BRV 20 mg/d = 100
BRV 5 mg/d = 97
PBO = 98
mITT populationb:
BRV 50 mg/d = 101
BRV 20 mg/d = 99
BRV 5 mg/d = 96
PBO = 96
Safety populationc:
BRV 50 mg/d = 101
BRV 20 mg/d = 100
BRV 5 mg/d = 97
PBO = 98
Age (mean and SD)d :
≥ 16 to 70 years
BRV 50 mg/d = 38.9 (12.3)
BRV 20 mg/d = 37.3 (13.3)
BRV 5 mg/d = 38.9 (11.6)
PBO = 37.5 (12.6)
Gender, male, n (%)d :
BRV 50 mg/d = 51 (50.5%)
BRV 20 mg/d = 52 (52.0%)
BRV 5 mg/d = 49 (50.5%)
PBO = 43 (43.9%)
Ethnicity white, n (%)d :
BRV 50 mg/d = 77 (76.2%)
BRV 20 mg/d = 70 (70.0%)
BRV 5 mg/d = 73 (75.3%)
PBO = 66 (67.3%)
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Biton 2014 (Continued)
Types of seizure: drug-resistant focal onset seizures
Interventions All treatment groups received their respective treatment in 2 equally divided doses per
day:
BRV 50 mg/d (BID)
BRV 20 mg/d (BID)
BRV 5 mg/d (BID)
PBO (BID)
Outcomes Primary outcomes:
1. Per cent reduction over PBO in adjusted FOS frequency per week during the treatment
period
2. Per cent reduction over PBO in 28-day adjusted FOS frequency during the treatment
period
Secondary outcomes:
1. ≥ 50% responder rate based on per cent reduction in seizure frequency/week from
baseline to the treatment period
2. Seizure freedom rate
Safety and tolerability outcomes:
1. Adverse events (AEs) and severity
2. Laboratory tests
3. Physical and neurological examination findings
4. Vital signs
5. Electrocardiography (ECG) recordings
Notes Trial registry number: N01253, NCT00464269
Sponsored by the manufacturer of BRV (UCB Pharma)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a central randomization method
(random permuted blocks) that stratified
for concomitant LEV use at study entry
(”yes“ or ”no“)”
Allocation concealment (selection bias) Low risk Quote: “treatment was assigned via an In-
teractive Voice Response System using a
central randomization method”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “matching placebo” was used to
maintain blinding
Quote: “patients and investigators were
blinded to treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: patients acted as outcome as-
sessors; patients self-reported seizure fre-
quency by completion of “seizure daily
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Biton 2014 (Continued)
record card” andwere effectively blinded by
matching placebo. Investigators, including
data analysts/statisticians, were also effec-
tively blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition was reported; modi-
fied intent-to-treat analysis was conducted,
resulting in the exclusion of 3 patients for
non-compliance and 1 patient as a clinical
outlier.Due to the small number of patients
excluded and the valid reasoning provided,
low risk of bias was still awarded
Selective reporting (reporting bias) Unclear risk Comment: protocol was not provided; all
outcomes defined in the methods were re-
ported in the results; however, no data were
reported for the number of patients tak-
ing placebo who reported at least 1 adverse
event
Quote: “the incidence of treatment-emer-
gent adverse events (TEAEs) was similar
in all four treatment groups. At least one
TEAE was reported during the treatment
period of 69 (71.1%) of 97patients onBRV
5 mg/day, 79 (79.0%) of 100 on BRV 20
mg/day, and 76 (75.2%) of 101 on BRV
50 mg/day”
Other bias Low risk Comment: none detected
French 2010
Methods Study design: phase 2b, randomised, double-blind, PBO-controlled, parallel-group,
multi-centre
Countries: Brazil, India, Mexico, and the USA
Duration:
1. Prospective baseline period (4 weeks)
2. Treatment period w/o up-titration (7 weeks)
3. 2-week drug-free period or entry into long-term open-label follow-up study
Participants Randomised population:
BRV 50 mg/d = 52
BRV 20 mg/d = 52
BRV 5 mg/d = 50
PBO = 54
ITT populationa :
BRV 50 mg/d = 52
BRV 20 mg/d = 52
BRV 5 mg/d = 50
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French 2010 (Continued)
PBO = 54
Safety populationc:
BRV 50 mg/d = 52
BRV 20 mg/d = 52
BRV 5 mg/d = 50
PBO = 54
Age (mean and SD)d :
≥ 16 to 65 years
BRV 50 mg/d = 30.9 (11.6)
BRV 20 mg/d = 35.3 (13.7)
BRV 5 mg/d = 32.7 (12.2)
PBO = 33.6 (11.3)
Gender, male, n (%)d :
BRV 50 mg/d = 28 (53.8)
BRV 20 mg/d = 28 (53.8)
BRV 5 mg/d = 30 (60.0)
PBO = 24 (44.4)
Ethnicity white, n (%)d :
BRV 50 mg/d = 12 (23.1)
BRV 20 mg/d = 22 (42.3)
BRV 5 mg/d = 16 (32.0)
PBO = 23 (42.6)
Types of seizure: drug-resistant focal onset seizures
Interventions All treatment groups received tablets, administered in 2 equally divided doses per day,
without up-titration
BRV 50 mg/d (BID)
BRV 20 mg/d (BID)
BRV 5 mg/d (BID)
PBO (BID)
Outcomes Primary outcome:
1. Per cent reduction over PBO in 28-day adjusted FOS frequency during the treatment
period
Secondary outcomes:
1. Absolute and percentage reduction from baseline in weekly FOS frequency during the
treatment period
2. ≥ 50% responder rate for FOS frequency/week from baseline during the treatment
period
3. Seizure freedom rate
Safety and tolerability outcomes:
1. Adverse events (AEs)
2. Laboratory tests
3. Physical and neurological examination findings
4. Vital signs
5. Electrocardiography (ECG) recordings
Notes Trial registry number: N01193, NCT00175825
Sponsored by the manufacturer of BRV (UCB Pharma)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “central randomization (random
permuted blocks)... stratified for the intake
of LEV... and of CBZ”
Allocation concealment (selection bias) Low risk Quote: “once a patient was eligible to
be randomized, the investigator called the
Central Randomization Center to receive a
kit number to assign to the patient”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the study was blinded, by use
of matching placebo tablets which were
identical in shape, size, and color to BRV
tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “efficacy assessments were made
from information recorded by the patients
on daily record cards”
Comment: patients were the outcome
assessors and were adequately blinded
throughout the study; moreover, the study
was double-blind, meaning that investiga-
tors, including those responsible for data
analysis, would also have been effectively
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition was reported and in-
tention-to-treat analysis was conducted;
however, a modified population was actu-
ally used. Two participants were excluded
as they did not take at least 1 dose of study
drug. Due to the small number of patients
excluded and the valid reasoning, a small
risk of bias was still awarded
Selective reporting (reporting bias) Low risk Comment: protocol was not provided;
however, all outcomes defined in methods
were reported in results
Other bias Low risk Comment: none detected
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Klein 2015
Methods Study design: phase 3, randomised, double-blind, PBO-controlled, parallel-group,
multi-centre
Countries: North America, Western Europe, Eastern Europe, Latin America, and Asia
Duration:
1. Prospective baseline period (8 weeks)
2. Treatment period (12 weeks)
3. Down-titration period (4 weeks)
4. Drug-free period (2 weeks) or entry into a long-term follow-up study
Participants Randomised population:
BRV 200 mg/d = 251
BRV 100 mg/d = 254
PBO = 263
ITT populationa :
BRV 200 mg/d = 249
BRV 100 mg/d = 252
PBO = 259
Safety populationc:
BRV 200 mg/d = 250
BRV 100 mg/d = 253
PBO = 261
Age (mean and SD)d :
≥ 16 to 80 years
BRV 200 mg/d = 39.8 (12.8)
BRV 100 mg/d = 39.1 (13.4)
PBO = 39.8 (12.5)
Gender, female, n (%)d :
BRV 200 mg/d = 117 (46.8%)
BRV 100 mg/d = 151 (59.7%)
PBO = 128 (49.0%)
Ethnicity white, n (%)d :
BRV 200 mg/d = 182 (72.8%)
BRV 100 mg/d = 182 (71.9%)
PBO = 189 (72.4%)
Types of seizure: drug-resistant focal onset seizures
Interventions All treatment groups received oral film-coated tablets, administered in 2 equally divided
doses per day, without up-titration
BRV 200 mg/d (BID)
BRV 100 mg/d (BID)
PBO (BID)
Outcomes Primary outcomes:
1. Per cent reduction over PBO in 28-day adjusted FOS frequency during the treatment
period
2. ≥ 50% responder rate based on per cent reduction in seizure frequency from baseline
to the treatment period
Secondary outcomes:
1. Per cent reduction in seizure frequency from baseline to the treatment period
2. Categorised per cent reduction from baseline in seizure frequency over the treatment
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period
3. Seizure freedom rate
Safety and tolerability outcomes:
1. Adverse events (AEs)
2. Laboratory tests
3. Vital signs
4. Electrocardiography (ECG) recordings
Notes Trial registry number: N01358, NCT01261325
Sponsored by the manufacturer of BRV (UCB Pharma)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a 1:1:1 central randomization
(random permuted blocks with a block size
of three) stratified by country, LEV sta-
tus (never used vs. prior use), and number
of AEDs previously used or discontinued
prior to study entry”
Allocation concealment (selection bias) Low risk Quote: “patients were assigned to a treat-
ment group at enrollment by an interactive
voice/computer response system (IVRS),
which was accessed by the investigator”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “all personnel who were involved
with the study were blinded to the pa-
tients’ treatment... Oral film-coated tablets
of BRV 10, 25, and 50 mg and match-
ing PBO tablets were used; these tablet
strengths were used both to help maintain
the blinding”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: patients reported seizure fre-
quency using seizure diaries and were
therefore the outcome assessors; patients
were sufficiently blinded by the matching
placebo. Investigators, including data ana-
lysts, were also effectively blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition was reported and in-
tention-to-treat analysis conducted; 8 par-
ticipants were excluded from the ITT pop-
ulation for the reasons specified: discontin-
uation for unspecified reasons before study
drug administration (n = 4), loss to follow-
up (n = 1), discontinuation due to a TEAE
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Klein 2015 (Continued)
(n = 2), and withdrawal of consent (n = 1)
. Due to the small number of participants
excluded, low risk of bias was still awarded
Selective reporting (reporting bias) Low risk Comment: protocol was not provided;
however, all outcomes defined in methods
were reported in results
Other bias Low risk Comment: none detected
Kwan 2014
Methods Study design: phase 3, randomised, double-blind, PBO-controlled, parallel-group, flex-
ible-dose, multi-centre
Countries: Austria, Belgium, Czech Republic, Germany, Hong Kong, India, Italy, Nor-
way, Republic of South Africa, Russian Federation, Singapore, South Korea, Sweden,
Taiwan, and Ukraine
Duration:
1. Prospective baseline period (4 weeks)
2. Treatment period (16 weeks) including 8-week dose-finding and 8-week maintenance
3. Down-titration period (2 weeks) and drug-free period (2 weeks) or entry into a long-
term follow-up study
Participants Randomised population:
BRV = 359
PBO = 121
ITT populationa :
BRV = 359
PBO = 121
Safety populationc:
BRV = 359
PBO = 121
Age (mean and SD)d :
≥ 16 to 70 years
BRV = 35.6 (11.5)
PBO = 36.5 (11.5)
Gender, male, n (%)d :
BRV = 181 (50.4)
PBO = 69 (57.0)
Ethnicity white, n (%)d :
BRV = 209 (58.2)
PBO = 69 (57.0)
Types of seizure: drug-resistant focal onset or generalised epilepsy
Interventions All treatment groups received tablets administered in 2 equally divided doses per day:
BRV 20, 50, 100, 150 mg/d (BID)
PBO (BID)
For participants randomised to BRV, BRV was initiated at 20 mg/d. Participants were
then up-titrated in a stepwise manner to 50, 100, or 150 mg/d at 2-week intervals based
30Brivaracetam add-on therapy for drug-resistant epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kwan 2014 (Continued)
on the investigator’s assessment of efficacy and tolerability
Outcomes Safety and tolerability outcomes:
1. Adverse events (AEs)
2. Discontinuations due to AEs
3. Vital signs
4. Physical and neurological examination findings
5. Laboratory tests
6. Electrocardiography (ECG) recordings
Primary efficacy outcome:
1. Per cent reduction in baseline-adjusted FOS frequency/week during the treatment
period over PBO
Secondary outcomes:
1. Median per cent reduction from baseline in FOS frequency/week
2. ≥ 50% responder rate in FOS frequency/week
3. Seizure freedom rate
4. Time to first, fifth, and 10th focal seizure
Notes Trial registry number N01254, NCT00504881
Sponsored by the manufacturer of BRV (UCB Pharma)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized 3:1 in
random permuted blocks to BRV or PBO
at the end of the baseline period. Random-
ization was stratified by epilepsy type (fo-
cal or generalized) (International League
Against Epilepsy, 1989), concomitant lev-
etiracetam (LEV) use (yes or no), and geo-
graphic region”
Allocation concealment (selection bias) Unclear risk Comment: details regarding allocation
concealment were not provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “matching PBO tablets”
Comment: appropriate measures were
taken to maintain blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the date and number of seizures
were recorded using a daily record card”
Comment: outcomes were self-reported by
the participants who remained appropri-
ately blinded throughout the study; more-
over, the study was double-blind, meaning
that investigators, including those respon-
sible for data analysis, would also have been
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effectively blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition was reported and
intent-to-treat analysis conducted, which
correctly included all randomised partici-
pants
Selective reporting (reporting bias) Low risk Comment: protocol was not provided;
however, all outcomes defined in methods
were reported in results
Other bias Unclear risk Quote: “patients were randomized 3:1 in
random permuted blocks to BRV or PBO”
Comment: 3:1 randomisation ratio pro-
duces uneven treatment group sizes, which
reduces the statistical power and can aug-
ment the placebo effect (Hey 2014)
Ryvlin 2014
Methods Study design: phase 3, randomised, double-blind, PBO-controlled, multi-centre
Countries: Poland, India, France, Germany, Spain, Italy, Switzerland,Hungary, Finland,
The Netherlands, Belgium, and the United Kingdom
Duration:
1. Prospective baseline period (8 weeks)
2. Treatment period (12 weeks)
3. Down-titration period (2 weeks) and drug-free period (2 weeks) or entry into a long-
term follow-up study
Participants Randomised population:
BRV 100 mg/d = 100
BRV 50 mg/d = 99
BRV 20 mg/d = 99
PBO = 100
ITT populationa :
BRV 100 mg/d = 100
BRV 50 mg/d = 99
BRV 20 mg/d = 99
PBO = 100
Safety populationc:
BRV 100 mg/d = 100
BRV 50 mg/d = 99
BRV 20 mg/d = 99
PBO = 100
Age (mean and SD)d :
≥ 16 to 70 years
BRV 100 mg/d = 38.0 (13.1)
BRV 50 mg/d = 38.9 (13.6)
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Ryvlin 2014 (Continued)
BRV 20 mg/d = 35.7 (12.5)
PBO = 36.4 (13.0)
Gender, male, n (%)d :
BRV 100 mg/d = 58 (58.0)
BRV 50 mg/d = 54 (54.5)
BRV 20 mg/d = 61 (61.6)
PBO = 54 (54.0)
Ethnicity white, n (%)d :
BRV 100 mg/d = 76 (76.0)
BRV 50 mg/d = 76 (76.8)
BRV 20 mg/d = 76 (76.8)
PBO = 77 (77.0)
Type of seizure: drug-resistant focal onset seizures
Interventions All treatment groups received their respective treatment in 2 equally divided doses per
day:
BRV 100 mg/d (BID)
BRV 50 mg/d (BID)
BRV 20 mg/d (BID)
PBO (BID)
Outcomes Primary outcome:
1. Per cent reduction over PBO in baseline-adjusted FOS frequency/week over the treat-
ment period
Secondary outcomes:
1. Median per cent reduction in seizure frequency/week from baseline to the treatment
period
2. ≥ 50% responder rate based on per cent reduction in seizure frequency/week from
baseline to the treatment period
3. Seizure freedom rate
Safety and tolerability outcomes:
1. Adverse events (AEs)
2. Laboratory tests
3. Physical and neurological examination findings
4. Vital signs
5. Electrocardiography (ECG) recordings
Notes Trial registry number: N01252, NCT00490035
Sponsored by the manufacturer of BRV (UCB Pharma)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “central randomisation... stratified
by geographic region and concomitant use
of LEV”
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Ryvlin 2014 (Continued)
Allocation concealment (selection bias) Low risk Quote: “treatment was assigned using cen-
tral randomization via an interactive voice
response system (IVRS)”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”
Comment: no evidence or explanation of
blinding provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “patients recorded the occurrence
of seizures on daily record cards”
Comment: participants were responsible
for the self-reporting of outcome measures;
however, no information is provided on
blinding of participants or study personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition was reported and in-
tent-to-treat analysis conducted; 1 partici-
pant was excluded from any analysis; how-
ever, that participant died from a subdural
haematoma before taking any study drug
Selective reporting (reporting bias) Low risk Comment: protocol was not provided;
however, all outcomes defined in methods
were reported in results
Other bias Low risk Comment: none detected
Van Paesschen 2013
Methods Study design: phase 2b, randomised, double-blind, PBO-controlled, parallel-group,
multi-centre
Countries: Belgium, Czech Republic, Finland, France, Germany, The Netherlands,
Poland, Spain, and the United Kingdom
Duration:
1. Prospective baseline period (4 weeks)
2. Treatment period (10 weeks: 3 weeks up-titration and 7 weeks maintenance)
3. Conversion period (2 weeks): entry into a long-term open-label follow-up study or
down-titration (2 weeks)
Participants Randomised population:
BRV 150 mg/d = 52
BRV 50 mg/d = 53
PBO = 52
ITT populationa :
BRV 150 mg/d = 52
BRV 50 mg/d = 53
PBO = 52
Safety populationc:
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Van Paesschen 2013 (Continued)
BRV 150 mg/d = 52
BRV 50 mg/d = 53
PBO = 52
Age (mean and SD)d :
≥ 16 to 65 years
BRV 150 mg/d = 34.4 (10.1)
BRV 50 mg/d = 38.2 (12.1)
PBO = 40.0 (11.7)
Gender, male, n (%)d :
BRV 150 mg/d = 21 (40.4)
BRV 50 mg/d = 24 (45.3)
PBO = 25 (48.1)
Ethnicity white, n (%)d :
BRV 150 mg/d = 52 (100.0)
BRV 50 mg/d = 53 (100.0)
PBO = 51 (98.1)
Type of seizure: drug-resistant focal onset seizures
Interventions All treatment groups received their respective treatment via oral capsules in 2 equally
divided doses per day:
BRV 150 mg/d (BID)
BRV 50 mg/d (BID)
PBO (BID)
Participants randomised to BRV 150 mg/d began the up-titration period on a dose of 50
mg/d. After 1 week, the dosage was increased to 100 mg/d and was then increased again
to 150 mg/d after 2 weeks. Patients were permitted 1 fallback during the maintenance
period to 100 mg/d
Participants randomised to BRV 50 mg/d started at a dose of 25 mg/d and were up-
titrated to 50 mg/d after 1 week. They were again permitted 1 fallback to 25 mg/d
during themaintenance period. Participants randomised to placebo continued to receive
placebo during the up-titration and maintenance periods
Outcomes Primary outcome:
1. Per cent reduction in baseline-adjusted FOS frequency/week over PBO during the
maintenance period
Secondary outcomes:
1. Reduction in FOS frequency/week over PBO during the treatment period
2. Per cent reduction from baseline in FOS frequency/week (maintenance and treatment
periods)
3. ≥ 50% responder rate in FOS seizure frequency from baseline during maintenance
and treatment periods
4. Seizure freedom rate
Safety and tolerability outcomes:
1. Treatment-emergent adverse events (TEAEs)
2. Physical and neurological examinations
3. Vital signs
4. Clinical laboratory tests
5. Electrocardiography (ECG) recordings
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Notes Trial registry number: N01114, NCT00175929
Sponsored by the manufacturer of BRV (UCB Pharma)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “central randomization method
(random permuted blocks) stratified for
concomitant use of LEV... and carba-
mazepine (CBZ)”
Allocation concealment (selection bias) Low risk Quote (from protocol): “each investigator
will receive numbered subjects’ kits. When
a subject is determined to be eligible for
randomization (at visit 2), the Investigator
or designee will call the Central Random-
ization Center (CRC) and will be assigned
a subject’s kit number, according to the op-
erating manual given by CRC”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “matching placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “efficacy assessments weremade us-
ing data recorded by the patients on daily
record cards and assessed by the investiga-
tor at each study visit”
Comment: participants were adequately
blindedbymatchingplacebo; the studywas
double-blind, meaning that investigators,
including those responsible for data analy-
sis, would also have been blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: attrition was reported and in-
tent-to-treat analysis conducted; no ran-
domised participants were excluded from
the ITT population
Selective reporting (reporting bias) Unclear risk Comment: protocol was provided; not all
outcomes defined in the protocol are re-
ported in the journal article
Quote: “secondary efficacy outcomes in-
cluded...”
Other bias Low risk Comment: none detected
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AE: adverse event; AED: antiepileptic drug; BID: twice a day; BRV: brivaracetam; CBZ: carbamazepine; ECG: electrocardiogram;
FOS: focal onset seizure; ITT: intention-to-treat; IVRS: interactive voice response system; LEV: levetiracetam; mITT: modified
intention-to-treat; PBO: placebo; TEAEs: treatment-emergent adverse effects.
aITT population was defined as all randomised patients who received at least one dose (≥ 1) of study drug, with the exception of Klein
2015, who defined ITT as all randomised patients who received at least one dose (≥ 1) of study drug and had at least one (≥ 1) post-
baseline seizure diary entry.
bBiton 2014 used a modified intent-to-population, excluding four participants (three for extreme non-compliance and one as a clinical
outlier).
cSafety population was defined as all randomised patients who received at least one dose (≥ 1) of study drug in Klein 2015. For all
other studies, the safety population was identical to the intent-to-treat population.
dCalculated using the safety population.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Lacroix 2007 Study was a meta-analysis of 2 trials already included in the review
Characteristics of ongoing studies [ordered by study ID]
NCT03083665
Trial name or title A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy
and Safety of Adjunctive Brivaracetam in Asian Subjects (≥ 16 to 80 Years of Age) With Partial Seizures With
or Without Secondary Generalization
Methods Randomised, double-blind, placebo-controlled, multi-centre study with parallel-group design
Countries: Japan, Malaysia, Philippines, Singapore, Taiwan, and Thailand
Participants Age: 16 to 80 years
Type of seizure: uncontrolled focal onset seizures with or without secondary generalisation
Interventions All treatment groups received tablets, administered in 2 equally divided doses per day, without up-titration
Film-coated tablets
BRV 50 mg/d
PBO
Outcomes Primary outcome:
1. Per cent change in FOS frequency during the 12-week treatment period
Secondary outcomes:
1. ≥ 50% responder rate based on FOS frequency per 28 days from baseline to the treatment period
2. Per cent change in FOS frequency per 28 days from baseline to treatment period
3. Categorised per cent change in FOS frequency per 28 days from baseline to treatment period
4. All seizure frequency (focal, generalised, and unclassified epileptic seizures) per 28 days during the 12-week
treatment period
5. Percentage of participants who are seizure free (focal, all epileptic seizures) during the 12-week treatment
period
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NCT03083665 (Continued)
6. Time to nth (first, fifth, tenth) focal seizure during the 12-week treatment period
Safety and tolerability outcomes:
1. Brivaracetam plasma concentration
2. Adverse events (AEs) and severity
2. Laboratory tests
3. Electrocardiogram (ECG)
4. Vital signs
5. Physical and neurological examination findings
6. Mental and psychiatric status
Starting date 22 August 2017
Contact information UCBCares@ucb.com
Notes Sponsored by UCB Pharma
AE: adverse event; BRV: brivaracetam; ECG: electrocardiography; FOS: focal-onset seizures; PBO: placebo.
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D A T A A N D A N A L Y S E S
Comparison 1. Brivaracetam vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50% or greater reduction in
seizure frequency (responder
rate)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 5 mg/d 2 302 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.97, 2.40]
1.2 20 mg/d BRV 3 504 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.18, 2.27]
1.3 50 mg/d BRV 4 611 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [1.50, 2.66]
1.4 100 mg/d BRV 2 717 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.42, 2.30]
1.5 150 mg/d BRV 1 104 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [0.86, 3.65]
1.6 200 mg/d BRV 1 514 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.33, 2.33]
1.7 All doses 6 2411 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.53, 2.14]
2 Seizure freedom 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 5 mg/d BRV 2 302 Risk Ratio (M-H, Fixed, 95% CI) 3.87 [0.65, 22.96]
2.2 20 mg/d BRV 3 551 Risk Ratio (M-H, Fixed, 95% CI) 2.98 [0.65, 13.61]
2.3 50 mg/d BRV 4 611 Risk Ratio (M-H, Fixed, 95% CI) 5.39 [1.42, 20.49]
2.4 100 mg/d BRV 2 717 Risk Ratio (M-H, Fixed, 95% CI) 7.19 [1.93, 26.85]
2.5 150 mg/d BRV 1 104 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.32, 27.91]
2.6 200 mg/d BRV 1 514 Risk Ratio (M-H, Fixed, 95% CI) 5.24 [1.16, 23.68]
2.7 All doses 6 2411 Risk Ratio (M-H, Fixed, 95% CI) 5.89 [2.30, 15.13]
3 Treatment withdrawal 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 5 mg/d BRV 2 302 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.93, 4.09]
3.2 20 mg/d BRV 3 504 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.40, 1.55]
3.3 50 mg/d BRV 4 611 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.56, 1.77]
3.4 100 mg/d BRV 2 717 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.88, 2.35]
3.5 150 mg/d BRV 1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.18, 3.19]
3.6 200 mg/d BRV 1 514 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.89, 2.88]
3.7 All doses 6 2411 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.94, 1.74]
4 Proportion of participants
who experienced adverse
events leading to treatment
withdrawal
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 5 mg/d BRV 2 302 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [0.71, 5.96]
4.2 20 mg/d BRV 3 504 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.46, 2.72]
4.3 50 mg/d BRV 4 611 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.58, 2.76]
4.4 100 mg/d BRV 2 717 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [1.01, 3.59]
4.5 150 mg/d BRV 1 104 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.26, 8.61]
4.6 200 mg/d BRV 1 514 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [0.83, 3.82]
4.7 All doses 6 2411 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.02, 2.33]
5 Proportion of participants who
experienced any adverse events
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 5 mg/d BRV 1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.67, 1.39]
5.2 20 mg/d BRV 2 305 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.86, 1.30]
5.3 50 mg/d BRV 3 410 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.91, 1.25]
5.4 100 mg/d BRV 2 717 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.04, 1.31]
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5.5 150 mg/d BRV 1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.73, 1.22]
5.6 200 mg/d BRV 1 514 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.99, 1.29]
5.7 All doses 5 2011 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [1.00, 1.17]
Analysis 1.1. Comparison 1 Brivaracetam vs placebo, Outcome 1 50% or greater reduction in seizure
frequency (responder rate).
Review: Brivaracetam add-on therapy for drug-resistant epilepsy
Comparison: 1 Brivaracetam vs placebo
Outcome: 1 50% or greater reduction in seizure frequency (responder rate)
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/d
Biton 2014 21/99 16/99 64.9 % 1.31 [ 0.73, 2.36 ]
French 2010 16/50 9/54 35.1 % 1.92 [ 0.93, 3.95 ]
Subtotal (95% CI) 149 153 100.0 % 1.53 [ 0.97, 2.40 ]
Total events: 37 (BRV), 25 (PBO)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
2 20 mg/d BRV
Biton 2014 23/100 16/99 35.9 % 1.42 [ 0.80, 2.53 ]
French 2010 23/52 9/54 19.7 % 2.65 [ 1.36, 5.19 ]
Ryvlin 2014 27/99 20/100 44.4 % 1.36 [ 0.82, 2.26 ]
Subtotal (95% CI) 251 253 100.0 % 1.64 [ 1.18, 2.27 ]
Total events: 73 (BRV), 45 (PBO)
Heterogeneity: Chi2 = 2.73, df = 2 (P = 0.26); I2 =27%
Test for overall effect: Z = 2.96 (P = 0.0031)
3 50 mg/d BRV
Biton 2014 33/102 16/99 30.0 % 2.00 [ 1.18, 3.40 ]
French 2010 29/52 9/54 16.3 % 3.35 [ 1.76, 6.37 ]
Ryvlin 2014 27/99 20/100 36.8 % 1.36 [ 0.82, 2.26 ]
Van Paesschen 2013 19/53 9/52 16.8 % 2.07 [ 1.03, 4.15 ]
Subtotal (95% CI) 306 305 100.0 % 2.00 [ 1.50, 2.66 ]
Total events: 108 (BRV), 54 (PBO)
Heterogeneity: Chi2 = 4.66, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 4.75 (P < 0.00001)
4 100 mg/d BRV
Klein 2015 98/254 56/263 73.3 % 1.81 [ 1.37, 2.40 ]
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(. . . Continued)
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ryvlin 2014 36/100 20/100 26.7 % 1.80 [ 1.12, 2.88 ]
Subtotal (95% CI) 354 363 100.0 % 1.81 [ 1.42, 2.30 ]
Total events: 134 (BRV), 76 (PBO)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.83 (P < 0.00001)
5 150 mg/d BRV
Van Paesschen 2013 16/52 9/52 100.0 % 1.78 [ 0.86, 3.65 ]
Subtotal (95% CI) 52 52 100.0 % 1.78 [ 0.86, 3.65 ]
Total events: 16 (BRV), 9 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
6 200 mg/d BRV
Klein 2015 94/251 56/263 100.0 % 1.76 [ 1.33, 2.33 ]
Subtotal (95% CI) 251 263 100.0 % 1.76 [ 1.33, 2.33 ]
Total events: 94 (BRV), 56 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000087)
7 All doses
Biton 2014 77/301 16/99 13.2 % 1.58 [ 0.97, 2.58 ]
French 2010 68/154 9/54 7.3 % 2.65 [ 1.42, 4.94 ]
Klein 2015 192/505 56/263 40.3 % 1.79 [ 1.38, 2.31 ]
Kwan 2014 114/359 20/121 16.4 % 1.92 [ 1.25, 2.95 ]
Ryvlin 2014 90/298 20/100 16.4 % 1.51 [ 0.98, 2.32 ]
Van Paesschen 2013 35/105 9/52 6.6 % 1.93 [ 1.00, 3.70 ]
Subtotal (95% CI) 1722 689 100.0 % 1.81 [ 1.53, 2.14 ]
Total events: 576 (BRV), 130 (PBO)
Heterogeneity: Chi2 = 2.53, df = 5 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 6.87 (P < 0.00001)
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Analysis 1.2. Comparison 1 Brivaracetam vs placebo, Outcome 2 Seizure freedom.
Review: Brivaracetam add-on therapy for drug-resistant epilepsy
Comparison: 1 Brivaracetam vs placebo
Outcome: 2 Seizure freedom
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/d BRV
Biton 2014 1/99 0/99 34.2 % 3.00 [ 0.12, 72.76 ]
French 2010 4/50 1/54 65.8 % 4.32 [ 0.50, 37.36 ]
Subtotal (95% CI) 149 153 100.0 % 3.87 [ 0.65, 22.96 ]
Total events: 5 (BRV), 1 (PBO)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
2 20 mg/d BRV
Biton 2014 1/100 0/99 21.9 % 2.97 [ 0.12, 72.05 ]
French 2010 4/99 1/54 56.4 % 2.18 [ 0.25, 19.03 ]
Ryvlin 2014 2/99 0/100 21.7 % 5.05 [ 0.25, 103.87 ]
Subtotal (95% CI) 298 253 100.0 % 2.98 [ 0.65, 13.61 ]
Total events: 7 (BRV), 1 (PBO)
Heterogeneity: Chi2 = 0.20, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
3 50 mg/d BRV
Biton 2014 4/102 0/99 20.3 % 8.74 [ 0.48, 160.20 ]
French 2010 4/52 1/54 39.3 % 4.15 [ 0.48, 35.95 ]
Ryvlin 2014 0/99 0/100 Not estimable
Van Paesschen 2013 5/53 1/52 40.4 % 4.91 [ 0.59, 40.57 ]
Subtotal (95% CI) 306 305 100.0 % 5.39 [ 1.42, 20.49 ]
Total events: 13 (BRV), 2 (PBO)
Heterogeneity: Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
4 100 mg/d BRV
Klein 2015 13/254 2/263 79.7 % 6.73 [ 1.53, 29.53 ]
Ryvlin 2014 4/100 0/100 20.3 % 9.00 [ 0.49, 165.00 ]
Subtotal (95% CI) 354 363 100.0 % 7.19 [ 1.93, 26.85 ]
Total events: 17 (BRV), 2 (PBO)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0033)
5 150 mg/d BRV
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(. . . Continued)
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Paesschen 2013 3/52 1/52 100.0 % 3.00 [ 0.32, 27.91 ]
Subtotal (95% CI) 52 52 100.0 % 3.00 [ 0.32, 27.91 ]
Total events: 3 (BRV), 1 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
6 200 mg/d BRV
Klein 2015 10/251 2/263 100.0 % 5.24 [ 1.16, 23.68 ]
Subtotal (95% CI) 251 263 100.0 % 5.24 [ 1.16, 23.68 ]
Total events: 10 (BRV), 2 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
7 All doses
Biton 2014 6/301 0/99 11.8 % 4.30 [ 0.24, 75.73 ]
French 2010 12/154 1/54 23.2 % 4.21 [ 0.56, 31.60 ]
Klein 2015 23/505 1/263 20.6 % 11.98 [ 1.63, 88.20 ]
Kwan 2014 7/359 0/121 11.7 % 5.08 [ 0.29, 88.35 ]
Ryvlin 2014 6/298 0/100 11.7 % 4.39 [ 0.25, 77.26 ]
Van Paesschen 2013 8/105 1/52 21.0 % 3.96 [ 0.51, 30.84 ]
Subtotal (95% CI) 1722 689 100.0 % 5.89 [ 2.30, 15.13 ]
Total events: 62 (BRV), 3 (PBO)
Heterogeneity: Chi2 = 0.83, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.69 (P = 0.00023)
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Analysis 1.3. Comparison 1 Brivaracetam vs placebo, Outcome 3 Treatment withdrawal.
Review: Brivaracetam add-on therapy for drug-resistant epilepsy
Comparison: 1 Brivaracetam vs placebo
Outcome: 3 Treatment withdrawal
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/d BRV
Biton 2014 15/99 5/99 51.0 % 3.00 [ 1.13, 7.94 ]
French 2010 4/50 5/54 49.0 % 0.86 [ 0.25, 3.04 ]
Subtotal (95% CI) 149 153 100.0 % 1.95 [ 0.93, 4.09 ]
Total events: 19 (BRV), 10 (PBO)
Heterogeneity: Chi2 = 2.36, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.78 (P = 0.076)
2 20 mg/d BRV
Biton 2014 7/100 5/99 28.1 % 1.39 [ 0.46, 4.22 ]
French 2010 1/52 5/54 27.4 % 0.21 [ 0.03, 1.72 ]
Ryvlin 2014 6/99 8/100 44.5 % 0.76 [ 0.27, 2.10 ]
Subtotal (95% CI) 251 253 100.0 % 0.78 [ 0.40, 1.55 ]
Total events: 14 (BRV), 18 (PBO)
Heterogeneity: Chi2 = 2.53, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.70 (P = 0.48)
3 50 mg/d BRV
Biton 2014 8/102 5/99 23.1 % 1.55 [ 0.53, 4.58 ]
French 2010 1/52 5/54 22.3 % 0.21 [ 0.03, 1.72 ]
Ryvlin 2014 11/99 8/100 36.2 % 1.39 [ 0.58, 3.31 ]
Van Paesschen 2013 2/53 4/52 18.4 % 0.49 [ 0.09, 2.56 ]
Subtotal (95% CI) 306 305 100.0 % 1.00 [ 0.56, 1.77 ]
Total events: 22 (BRV), 22 (PBO)
Heterogeneity: Chi2 = 4.03, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.01 (P = 0.99)
4 100 mg/d BRV
Klein 2015 29/254 17/263 67.6 % 1.77 [ 1.00, 3.13 ]
Ryvlin 2014 6/100 8/100 32.4 % 0.75 [ 0.27, 2.08 ]
Subtotal (95% CI) 354 363 100.0 % 1.44 [ 0.88, 2.35 ]
Total events: 35 (BRV), 25 (PBO)
Heterogeneity: Chi2 = 2.05, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.45 (P = 0.15)
5 150 mg/d BRV
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(. . . Continued)
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Van Paesschen 2013 3/52 4/52 100.0 % 0.75 [ 0.18, 3.19 ]
Subtotal (95% CI) 52 52 100.0 % 0.75 [ 0.18, 3.19 ]
Total events: 3 (BRV), 4 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
6 200 mg/d BRV
Klein 2015 26/251 17/263 100.0 % 1.60 [ 0.89, 2.88 ]
Subtotal (95% CI) 251 263 100.0 % 1.60 [ 0.89, 2.88 ]
Total events: 26 (BRV), 17 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
7 All doses
Biton 2014 30/301 5/99 10.8 % 1.97 [ 0.79, 4.95 ]
French 2010 6/154 5/54 10.6 % 0.42 [ 0.13, 1.32 ]
Klein 2015 55/505 17/263 32.1 % 1.68 [ 1.00, 2.84 ]
Kwan 2014 36/359 10/121 21.5 % 1.21 [ 0.62, 2.37 ]
Ryvlin 2014 23/298 8/100 17.2 % 0.96 [ 0.45, 2.09 ]
Van Paesschen 2013 5/105 4/52 7.7 % 0.62 [ 0.17, 2.21 ]
Subtotal (95% CI) 1722 689 100.0 % 1.27 [ 0.94, 1.74 ]
Total events: 155 (BRV), 49 (PBO)
Heterogeneity: Chi2 = 7.32, df = 5 (P = 0.20); I2 =32%
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 1.4. Comparison 1 Brivaracetam vs placebo, Outcome 4 Proportion of participants who
experienced adverse events leading to treatment withdrawal.
Review: Brivaracetam add-on therapy for drug-resistant epilepsy
Comparison: 1 Brivaracetam vs placebo
Outcome: 4 Proportion of participants who experienced adverse events leading to treatment withdrawal
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/d BRV
Biton 2014 8/99 2/99 40.9 % 4.00 [ 0.87, 18.37 ]
French 2010 2/50 3/54 59.1 % 0.72 [ 0.13, 4.13 ]
Subtotal (95% CI) 149 153 100.0 % 2.06 [ 0.71, 5.96 ]
Total events: 10 (BRV), 5 (PBO)
Heterogeneity: Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 1.34 (P = 0.18)
2 20 mg/d BRV
Biton 2014 5/100 2/99 22.5 % 2.48 [ 0.49, 12.46 ]
French 2010 1/52 3/54 32.9 % 0.35 [ 0.04, 3.22 ]
Ryvlin 2014 4/99 4/100 44.6 % 1.01 [ 0.26, 3.93 ]
Subtotal (95% CI) 251 253 100.0 % 1.12 [ 0.46, 2.72 ]
Total events: 10 (BRV), 9 (PBO)
Heterogeneity: Chi2 = 2.01, df = 2 (P = 0.37); I2 =1%
Test for overall effect: Z = 0.25 (P = 0.80)
3 50 mg/d BRV
Biton 2014 6/102 2/99 18.5 % 2.91 [ 0.60, 14.08 ]
French 2010 1/52 3/54 26.8 % 0.35 [ 0.04, 3.22 ]
Ryvlin 2014 5/99 4/100 36.3 % 1.26 [ 0.35, 4.56 ]
Van Paesschen 2013 2/53 2/52 18.4 % 0.98 [ 0.14, 6.71 ]
Subtotal (95% CI) 306 305 100.0 % 1.27 [ 0.58, 2.76 ]
Total events: 14 (BRV), 11 (PBO)
Heterogeneity: Chi2 = 2.44, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
4 100 mg/d BRV
Klein 2015 21/254 10/263 71.1 % 2.17 [ 1.04, 4.53 ]
Ryvlin 2014 5/100 4/100 28.9 % 1.25 [ 0.35, 4.52 ]
Subtotal (95% CI) 354 363 100.0 % 1.91 [ 1.01, 3.59 ]
Total events: 26 (BRV), 14 (PBO)
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
0.01 0.1 1 10 100
Favours PBO Favours BRV
(Continued . . . )
46Brivaracetam add-on therapy for drug-resistant epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.00 (P = 0.045)
5 150 mg/d BRV
Van Paesschen 2013 3/52 2/52 100.0 % 1.50 [ 0.26, 8.61 ]
Subtotal (95% CI) 52 52 100.0 % 1.50 [ 0.26, 8.61 ]
Total events: 3 (BRV), 2 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
6 200 mg/d BRV
Klein 2015 17/251 10/263 100.0 % 1.78 [ 0.83, 3.82 ]
Subtotal (95% CI) 251 263 100.0 % 1.78 [ 0.83, 3.82 ]
Total events: 17 (BRV), 10 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
7 All doses
Biton 2014 19/301 2/99 7.9 % 3.12 [ 0.74, 13.18 ]
French 2010 4/154 3/54 11.6 % 0.47 [ 0.11, 2.02 ]
Klein 2015 38/505 10/263 34.4 % 1.98 [ 1.00, 3.91 ]
Kwan 2014 22/359 6/121 23.5 % 1.24 [ 0.51, 2.98 ]
Ryvlin 2014 14/298 4/100 15.7 % 1.17 [ 0.40, 3.49 ]
Van Paesschen 2013 5/105 2/52 7.0 % 1.24 [ 0.25, 6.17 ]
Subtotal (95% CI) 1722 689 100.0 % 1.54 [ 1.02, 2.33 ]
Total events: 102 (BRV), 27 (PBO)
Heterogeneity: Chi2 = 4.55, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
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Analysis 1.5. Comparison 1 Brivaracetam vs placebo, Outcome 5 Proportion of participants who
experienced any adverse events.
Review: Brivaracetam add-on therapy for drug-resistant epilepsy
Comparison: 1 Brivaracetam vs placebo
Outcome: 5 Proportion of participants who experienced any adverse events
Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 5 mg/d BRV
French 2010 26/50 29/54 100.0 % 0.97 [ 0.67, 1.39 ]
Subtotal (95% CI) 50 54 100.0 % 0.97 [ 0.67, 1.39 ]
Total events: 26 (BRV), 29 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
2 20 mg/d BRV
French 2010 29/52 29/54 35.0 % 1.04 [ 0.73, 1.47 ]
Ryvlin 2014 56/99 53/100 65.0 % 1.07 [ 0.83, 1.37 ]
Subtotal (95% CI) 151 154 100.0 % 1.06 [ 0.86, 1.30 ]
Total events: 85 (BRV), 82 (PBO)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
3 50 mg/d BRV
French 2010 28/52 29/54 24.0 % 1.00 [ 0.70, 1.43 ]
Ryvlin 2014 62/99 53/100 44.5 % 1.18 [ 0.93, 1.50 ]
Van Paesschen 2013 36/53 37/52 31.5 % 0.95 [ 0.74, 1.23 ]
Subtotal (95% CI) 204 206 100.0 % 1.07 [ 0.91, 1.25 ]
Total events: 126 (BRV), 119 (PBO)
Heterogeneity: Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
4 100 mg/d BRV
Klein 2015 173/254 155/263 74.2 % 1.16 [ 1.01, 1.32 ]
Ryvlin 2014 63/100 53/100 25.8 % 1.19 [ 0.94, 1.51 ]
Subtotal (95% CI) 354 363 100.0 % 1.16 [ 1.04, 1.31 ]
Total events: 236 (BRV), 208 (PBO)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
5 150 mg/d BRV
Van Paesschen 2013 35/52 37/52 100.0 % 0.95 [ 0.73, 1.22 ]
Subtotal (95% CI) 52 52 100.0 % 0.95 [ 0.73, 1.22 ]
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Study or subgroup BRV PBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 35 (BRV), 37 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
6 200 mg/d BRV
Klein 2015 167/251 155/263 100.0 % 1.13 [ 0.99, 1.29 ]
Subtotal (95% CI) 251 263 100.0 % 1.13 [ 0.99, 1.29 ]
Total events: 167 (BRV), 155 (PBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
7 All doses
French 2010 83/154 29/54 8.7 % 1.00 [ 0.75, 1.34 ]
Klein 2015 340/505 155/263 41.3 % 1.14 [ 1.02, 1.29 ]
Kwan 2014 237/359 79/121 23.9 % 1.01 [ 0.87, 1.17 ]
Ryvlin 2014 181/298 53/100 16.1 % 1.15 [ 0.93, 1.41 ]
Van Paesschen 2013 71/105 37/52 10.0 % 0.95 [ 0.76, 1.18 ]
Subtotal (95% CI) 1421 590 100.0 % 1.08 [ 1.00, 1.17 ]
Total events: 912 (BRV), 353 (PBO)
Heterogeneity: Chi2 = 3.51, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
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A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. (Brivaracetam):AB,KW,MC,MH,TI AND CENTRAL:TARGET
2. (monotherap* NOT (adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*)):TI ANDCENTRAL:
TARGET
3. #1 NOT #2
#3 AND >23/03/2017:CRSCREATED
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Appendix 2. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2011).
1. Brivaracetam.tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$)).ti.
16. 14 not 15
17. remove duplicates from 16
18. limit 17 to ed=20170323-20181009
19. 17 not (1$ or 2$).ed.
20. 19 and (2017$ or 2018$).dt.
21. 18 or 20
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | Brivaracetam | First posted from 03/23/2017 to 10/09/2018
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: Brivaracetam
Recruitment status: All
Date of registration between 23/03/2017 and 09/10/2018
Phases: All
C O N T R I B U T I O N S O F A U T H O R S
Rebecca Bresnahan: assessed study eligibility and performed data extraction and risk of bias assessment. Responsible for the primary
conduct and writing of this current review update.
Mariangela Panebianco: assessed study eligibility and performed data extraction and risk of bias assessment for this current review
update.
Anthony Marson: arbitrated discussions when necessary.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Review authorship has changed since publication of the review protocol. Rebecca Bresnahan and Mariangela Panebianco have since
been instated as two review authors, with Rebecca Bresnahan primarily responsible for the conduct and reporting of the review. Qin
Zhou, Cai-you Hu, Wei Zhang, and Yong-hong Huang remain acknowledged for their writing of the original protocol and for their
contribution to the background section and methods section of the current review, which we adapted from the original review protocol.
We had stated in the protocol that we would assess funnel plot asymmetry as an indication of publication bias. However, our review
included fewer than 10 studies, so we did not produce any funnel plots for defined outcomes.
We had further specified that we would conduct subgroup analyses according to the different dose groups of brivaracetam, as well as
the different age groups of participants. However, we were able to conduct subgroup analysis only according to dose groups. All of the
included studies comprised purely adult patient populations; consequently, subgroup analysis according to age group was not possible.
Finally, we had planned to conduct sensitivity analyses. Specifically, we had intended to repeat the meta-analyses whilst excluding
unpublished studies and then whilst excluding studies that had been published only as abstracts. All of the included studies were
published as full-length journal articles; therefore, neither sensitivity analysis was necessary.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Drug Interactions; Drug Resistant Epilepsy [∗drug therapy]; Drug Therapy, Com-
bination; Patient Dropouts [statistics & numerical data]; Pyrrolidinones [adverse effects; ∗therapeutic use]; Randomized Controlled
Trials as Topic
MeSH check words
Humans
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